Nothing Special   »   [go: up one dir, main page]

MX342945B - Profármacos de ácido nucleico novedosos y métodos de uso de los mismos. - Google Patents

Profármacos de ácido nucleico novedosos y métodos de uso de los mismos.

Info

Publication number
MX342945B
MX342945B MX2012000380A MX2012000380A MX342945B MX 342945 B MX342945 B MX 342945B MX 2012000380 A MX2012000380 A MX 2012000380A MX 2012000380 A MX2012000380 A MX 2012000380A MX 342945 B MX342945 B MX 342945B
Authority
MX
Mexico
Prior art keywords
nucleic acid
acid prodrugs
methods use
novel nucleic
prodrugs
Prior art date
Application number
MX2012000380A
Other languages
English (en)
Other versions
MX2012000380A (es
Inventor
Meena Meena
Iwamoto Naoki
L Verdine Gregory
Original Assignee
Ontorii Inc *
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43429503&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX342945(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ontorii Inc * filed Critical Ontorii Inc *
Publication of MX2012000380A publication Critical patent/MX2012000380A/es
Publication of MX342945B publication Critical patent/MX342945B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/7115Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/712Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/7125Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06Pyrimidine radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

La presente invención se refiere a profármacos de ácido nucleico y profármacos de ácido nucleico que comprenden restos de fósforo quiral. También se describen en la presente métodos para preparar y utilizar profármacos de ácido nucleico y profármacos de ácido nucleico que comprenden restos de fósforo quiral.
MX2012000380A 2009-07-06 2010-07-06 Profármacos de ácido nucleico novedosos y métodos de uso de los mismos. MX342945B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22336909P 2009-07-06 2009-07-06
US24272209P 2009-09-15 2009-09-15
PCT/US2010/041068 WO2011005761A1 (en) 2009-07-06 2010-07-06 Novel nucleic acid prodrugs and methods use thereof

Publications (2)

Publication Number Publication Date
MX2012000380A MX2012000380A (es) 2012-05-23
MX342945B true MX342945B (es) 2016-10-18

Family

ID=43429503

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012000380A MX342945B (es) 2009-07-06 2010-07-06 Profármacos de ácido nucleico novedosos y métodos de uso de los mismos.

Country Status (15)

Country Link
US (2) US9744183B2 (es)
EP (1) EP2451461A4 (es)
JP (2) JP5998326B2 (es)
KR (1) KR101885383B1 (es)
CN (1) CN102596204B (es)
AU (1) AU2010270714B2 (es)
BR (1) BR112012000828A8 (es)
CA (1) CA2767253A1 (es)
CL (1) CL2012000021A1 (es)
IL (1) IL217370A (es)
IN (1) IN2012DN00720A (es)
MX (1) MX342945B (es)
RU (1) RU2612521C2 (es)
SG (2) SG10201403841QA (es)
WO (1) WO2011005761A1 (es)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101806314B1 (ko) * 2008-04-03 2017-12-07 스프링 뱅크 파마슈티칼스, 인크. 바이러스 감염증을 치료하기 위한 조성물 및 방법
WO2010064146A2 (en) 2008-12-02 2010-06-10 Chiralgen, Ltd. Method for the synthesis of phosphorus atom modified nucleic acids
RU2612521C2 (ru) 2009-07-06 2017-03-09 Онтории, Инк. Новые пролекарства нуклеиновых кислот и способы их применения
JP5868324B2 (ja) 2010-09-24 2016-02-24 株式会社Wave Life Sciences Japan 不斉補助基
SG10201700554VA (en) * 2011-07-19 2017-03-30 Wave Life Sciences Pte Ltd Methods for the synthesis of functionalized nucleic acids
WO2014010250A1 (en) 2012-07-13 2014-01-16 Chiralgen, Ltd. Asymmetric auxiliary group
US9617547B2 (en) 2012-07-13 2017-04-11 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant
WO2014012081A2 (en) * 2012-07-13 2014-01-16 Ontorii, Inc. Chiral control
US9950001B2 (en) 2012-08-20 2018-04-24 The Regents Of The University Of California Polynucleotides having bioreversible groups
EP2961388B1 (en) * 2013-03-01 2019-04-24 Astex Pharmaceuticals, Inc. Drug combinations
WO2015108046A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤
EP3095461A4 (en) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
JPWO2015108048A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
AU2015207773B2 (en) 2014-01-16 2021-06-17 Wave Life Sciences Ltd. Chiral design
RU2708237C2 (ru) 2014-08-22 2019-12-05 Общество с ограниченной ответственностью "НооГен" Модифицированные олигонуклеотиды и способ их получения
WO2016096938A1 (en) 2014-12-16 2016-06-23 Roche Innovation Center Copenhagen A/S Chiral toxicity screening method
DK3234134T3 (da) 2014-12-17 2020-07-27 Proqr Therapeutics Ii Bv Målrettet rna-redigering
US20180207197A1 (en) * 2015-06-26 2018-07-26 Kyowa Hakko Kirin Co., Ltd. Oligonucleotide derivative
MA43072A (fr) 2015-07-22 2018-05-30 Wave Life Sciences Ltd Compositions d'oligonucléotides et procédés associés
MX2018003992A (es) 2015-10-09 2018-08-01 Wave Life Sciences Ltd Composiciones oligonucleotidicas y sus metodos.
EP3426671A4 (en) * 2016-03-11 2019-11-20 Spring Bank Pharmaceuticals, Inc. COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF INFECTIONS
JP7286320B2 (ja) 2016-03-13 2023-06-05 ウェイブ ライフ サイエンシズ リミテッド ホスホラミダイト及びオリゴヌクレオチド合成のための組成物並びに方法
EP3430021A1 (en) * 2016-03-18 2019-01-23 Roche Innovation Center Copenhagen A/S Acyl-protected l-lna-guanosine monomers
EA201892366A1 (ru) 2016-04-18 2019-03-29 Сарепта Терапьютикс, Инк. Антисмысловые олигомеры и способы их применения для лечения заболеваний, связанных с геном кислой альфа-глюкозидазы
EA201892467A1 (ru) 2016-04-29 2019-05-31 Сарепта Терапьютикс, Инк. Олигонуклеотидные аналоги, нацеленные на lmna человека
MA45270A (fr) 2016-05-04 2017-11-09 Wave Life Sciences Ltd Compositions d'oligonucléotides et procédés associés
EP3463386A4 (en) 2016-06-03 2020-03-04 Wave Life Sciences Ltd. OLIGONUCLEOTIDES, COMPOSITIONS AND METHOD THEREFOR
CA3024944A1 (en) 2016-06-22 2017-12-28 Proqr Therapeutics Ii B.V. Single-stranded rna-editing oligonucleotides
EP3478697A1 (en) 2016-06-30 2019-05-08 Sarepta Therapeutics, Inc. Exon skipping oligomers for muscular dystrophy
CR20190071A (es) * 2016-07-15 2019-10-29 Sperovie Biosciences Inc Compuestos, composiciones y métodos para el tratamiento de enfermedades
JP2019532027A (ja) 2016-08-17 2019-11-07 ソルスティス バイオロジクス,リミティッド ポリヌクレオチド構築物
EP3503730B1 (en) 2016-08-23 2023-09-27 Dicerna Pharmaceuticals, Inc. Compositions comprising reversibly modified oligonucleotides and uses thereof
NZ751483A (en) 2016-09-01 2022-07-01 Proqr Therapeutics Ii Bv Chemically modified single-stranded rna-editing oligonucleotides
CN110088113A (zh) 2016-11-23 2019-08-02 波涛生命科学有限公司 用于亚磷酰胺和寡核苷酸合成的组合物和方法
JOP20170192A1 (ar) 2016-12-01 2019-01-30 Takeda Pharmaceuticals Co داي نوكليوتيد حلقي
PL3554554T3 (pl) 2016-12-19 2022-12-19 Sarepta Therapeutics, Inc. Koniugaty oligomerów z pominięciem egzonu w dystrofii mięśniowej
EP3554552B1 (en) 2016-12-19 2022-08-17 Sarepta Therapeutics, Inc. Exon skipping oligomer conjugates for muscular dystrophy
DK3554553T3 (da) 2016-12-19 2022-09-19 Sarepta Therapeutics Inc Exon-overspringnings-oligomerkonjugat til muskeldystrofi
EP3603648A4 (en) 2017-03-29 2020-12-30 Shionogi & Co., Ltd COMPLEX OF NUCLEIC ACID MEDICINAL AND MULTI-BRANCHED LIPID
EP3601309A1 (en) 2017-03-29 2020-02-05 Roche Innovation Center Copenhagen A/S Orthogonal protecting groups for the preparation of stereodefined phosphorothioate oligonucleotides
EP3630199A4 (en) * 2017-06-02 2021-11-10 Wave Life Sciences Ltd. OLIGONUCLEOTIDE COMPOSITIONS AND METHODS FOR THEIR USE
WO2018223081A1 (en) 2017-06-02 2018-12-06 Wave Life Sciences Ltd. Oligonucleotide compositions and methods of use thereof
US11718638B2 (en) 2017-06-21 2023-08-08 Wave Life Sciences Ltd. Compounds, compositions and methods for synthesis
EP3645546A4 (en) 2017-06-30 2021-12-01 Solstice Biologics, Ltd. CHIRAL PHOSPHORAMIDITIS AUXILIARIES AND THEIR METHODS OF USE
EP3664816A4 (en) * 2017-08-08 2021-05-19 Wave Life Sciences Ltd. OLIGONUCLEOTIDE COMPOSITIONS AND METHOD FOR THEREFORE
JP7472018B2 (ja) 2017-09-18 2024-04-22 ウェーブ ライフ サイエンシーズ リミテッド オリゴヌクレオチド調製のための技術
EA201991450A1 (ru) 2017-09-22 2019-12-30 Сарепта Терапьютикс, Инк. Конъюгаты олигомеров для пропуска экзона при мышечной дистрофии
US20200254002A1 (en) 2017-09-28 2020-08-13 Sarepta Therapeutics, Inc. Combination therapies for treating muscular dystrophy
WO2019067975A1 (en) 2017-09-28 2019-04-04 Sarepta Therapeutics, Inc. POLYTHERAPIES FOR TREATING MUSCLE DYSTROPHY
EP3687577A1 (en) 2017-09-28 2020-08-05 Sarepta Therapeutics, Inc. Combination therapies for treating muscular dystrophy
CN107892710B (zh) * 2017-10-10 2021-04-13 河北大学 一种易于回收循环使用的负载型铂配合物氧化剂及其制备方法和应用
WO2019075357A1 (en) 2017-10-12 2019-04-18 Wave Life Sciences Ltd. OLIGONUCLEOTIDE COMPOSITIONS AND RELATED METHODS
US11555189B2 (en) 2017-10-18 2023-01-17 Sarepta Therapeutics, Inc. Antisense oligomer compounds
US10765760B2 (en) 2018-05-29 2020-09-08 Sarepta Therapeutics, Inc. Exon skipping oligomer conjugates for muscular dystrophy
EP4219717A3 (en) 2018-06-13 2023-12-20 Sarepta Therapeutics, Inc. Exon skipping oligomers for muscular dystrophy
TW202020153A (zh) 2018-07-27 2020-06-01 美商薩羅塔治療公司 用於肌肉萎縮症之外顯子跳躍寡聚物
US11639354B2 (en) 2018-07-31 2023-05-02 Fimecs, Inc. Heterocyclic compound
SG11202104960PA (en) 2018-12-13 2021-06-29 Sarepta Therapeutics Inc Exon skipping oligomer conjugates for muscular dystrophy
CN111423483A (zh) * 2019-01-10 2020-07-17 南开大学 环二核苷酸前药分子及其制备方法和应用
US20220193246A1 (en) 2019-04-18 2022-06-23 Sarepta Therapeutics, Inc. Compositions for treating muscular dystrophy
US20220402935A1 (en) 2019-07-31 2022-12-22 Fimecs, Inc. Heterocyclic compound
US20230149560A1 (en) 2020-04-20 2023-05-18 Massachusetts Institute Of Technology Lipid compositions for delivery of sting agonist compounds and uses thereof
US20230203484A1 (en) 2020-05-22 2023-06-29 Wave Life Sciences Ltd. Double stranded oligonucleotide compositions and methods relating thereto
TW202241454A (zh) * 2021-02-01 2022-11-01 日商第一三共股份有限公司 抗體-免疫賦活化劑共軛物之新穎製造方法
WO2023055774A1 (en) 2021-09-30 2023-04-06 Sarepta Therapeutics, Inc. Antisense oligonucleotides having one or more abasic units
WO2023152371A1 (en) 2022-02-14 2023-08-17 Proqr Therapeutics Ii B.V. Guide oligonucleotides for nucleic acid editing in the treatment of hypercholesterolemia
WO2024013361A1 (en) 2022-07-15 2024-01-18 Proqr Therapeutics Ii B.V. Oligonucleotides for adar-mediated rna editing and use thereof
WO2024013360A1 (en) 2022-07-15 2024-01-18 Proqr Therapeutics Ii B.V. Chemically modified oligonucleotides for adar-mediated rna editing
WO2024064237A2 (en) 2022-09-21 2024-03-28 Sarepta Therapeutics, Inc. Dmd antisense oligonucleotide-mediated exon skipping efficiency
GB202215614D0 (en) 2022-10-21 2022-12-07 Proqr Therapeutics Ii Bv Heteroduplex rna editing oligonucleotide complexes
WO2024093947A1 (zh) * 2022-10-31 2024-05-10 大睿生物医药科技(上海)有限公司 向细胞内递送siRNA的前药
WO2024110565A1 (en) 2022-11-24 2024-05-30 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of hereditary hfe-hemochromatosis
GB202218090D0 (en) 2022-12-01 2023-01-18 Proqr Therapeutics Ii Bv Antisense oligonucleotides for the treatment of aldehyde dehydrogenase 2 deficiency
WO2024121373A1 (en) 2022-12-09 2024-06-13 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of cardiovascular disease
GB202300865D0 (en) 2023-01-20 2023-03-08 Proqr Therapeutics Ii Bv Delivery of oligonucleotides
WO2024175550A1 (en) 2023-02-20 2024-08-29 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of atherosclerotic cardiovascular disease
WO2024206175A1 (en) 2023-03-24 2024-10-03 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of neurological disorders
GB202304363D0 (en) 2023-03-24 2023-05-10 Proqr Therapeutics Ii Bv Chemically modified antisense oligonucleotides for use in RNA editing
WO2024200472A1 (en) 2023-03-27 2024-10-03 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of liver disease
WO2024227040A1 (en) 2023-04-27 2024-10-31 Sarepta Therapeutics, Inc. Antisense oligomers for treatment of chronic kidney disease

Family Cites Families (687)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2878264A (en) 1959-03-17 Substituted amino alcohols
CH372667A (de) 1957-09-26 1963-10-31 Robins Co Inc A H Verfahren zur Herstellung von 3-Aryl-3-pyrrolidinolen
US3135766A (en) 1961-10-03 1964-06-02 Mead Johnson & Co 3-substituted-3-pyrrolidinols
US3484473A (en) 1967-05-12 1969-12-16 Buckman Labor Inc Methylene bisesters of thiolsulfonic acids
DE1934150A1 (de) 1968-07-10 1970-01-15 Pennwalt Corp Neue 1-Alkanoyloxy-1,2,4,5-tetrahydro-3H,3-benzazepine
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US3745162A (en) 1970-08-31 1973-07-10 Robins Co Inc A H 1,2,3,4-tetrahydroisoquinoline-2-(thio)-carboxamides
GB1448437A (en) 1973-02-24 1976-09-08 Beecham Group Ltd Diphenylpropylamines
US4022791A (en) 1975-06-03 1977-05-10 Pfizer Inc. 2-Aminomethyl-3,4-dihydronaphthalenes
GB1504424A (en) 1975-08-09 1978-03-22 Beecham Group Ltd Isoquinoline-derived aminoethers
BR7807288A (pt) 1977-11-08 1979-06-12 Genentech Inc Processo para sintese de polinucleotidos
DD133885B1 (de) 1978-01-04 1981-02-25 Hans Lehmann Mittel zur bekaempfung von phytopathogenen bakterien und pilzen
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US5132418A (en) 1980-02-29 1992-07-21 University Patents, Inc. Process for preparing polynucleotides
US4500707A (en) 1980-02-29 1985-02-19 University Patents, Inc. Nucleosides useful in the preparation of polynucleotides
US4668777A (en) 1981-03-27 1987-05-26 University Patents, Inc. Phosphoramidite nucleoside compounds
US4973679A (en) 1981-03-27 1990-11-27 University Patents, Inc. Process for oligonucleo tide synthesis using phosphormidite intermediates
US4415732A (en) 1981-03-27 1983-11-15 University Patents, Inc. Phosphoramidite compounds and processes
US4542142A (en) 1982-11-22 1985-09-17 Roussel Uclaf Insecticidal cyclopropane carboxylic acid derivatives with 3-unsaturated-side chain
DE3329892A1 (de) 1983-08-18 1985-03-07 Köster, Hubert, Prof. Dr., 2000 Hamburg Verfahren zur herstellung von oligonucleotiden
US5118800A (en) 1983-12-20 1992-06-02 California Institute Of Technology Oligonucleotides possessing a primary amino group in the terminal nucleotide
US5643889A (en) 1984-07-11 1997-07-01 Temple University-Of The Commonwealth System Of Pennsylvania Cholesterol conjugates of 2'5'-oligoadenylate derivatives and antiviral uses thereof
FR2567892B1 (fr) 1984-07-19 1989-02-17 Centre Nat Rech Scient Nouveaux oligonucleotides, leur procede de preparation et leurs applications comme mediateurs dans le developpement des effets des interferons
US5367066A (en) 1984-10-16 1994-11-22 Chiron Corporation Oligonucleotides with selectably cleavable and/or abasic sites
FR2575751B1 (fr) 1985-01-08 1987-04-03 Pasteur Institut Nouveaux nucleosides de derives de l'adenosine, leur preparation et leurs applications biologiques
FR2576898B1 (fr) 1985-02-01 1988-01-08 Lafon Labor Derives de 3-phenyl-tetrahydropyridine, procede de preparation et utilisation en therapeutique
JPH0658512B2 (ja) 1985-04-12 1994-08-03 富士写真フイルム株式会社 ハロゲン化銀写真感光材料
US4659774A (en) 1985-11-01 1987-04-21 American Hoechst Corporation Support for solid-phase oligonucleotide synthesis
US4735949A (en) 1986-02-18 1988-04-05 Warner-Lambert Company Disubstituted-7-pyrrolidinonaphthyridine antibacterial agents
US4840956A (en) 1986-02-18 1989-06-20 Warner-Lambert Company Novel disubstituted-7-pyrrolidinoquinoline antibacterial agents
IL83663A0 (en) 1986-10-27 1988-01-31 Robins Co Inc A H Preparation of 3-pyrrolidinols
JP2828642B2 (ja) 1987-06-24 1998-11-25 ハワード フローレイ インスティテュト オブ イクスペリメンタル フィジオロジー アンド メディシン ヌクレオシド誘導体
ES2045028T3 (es) 1987-07-30 1994-01-16 Univ Bar Ilan Esteres de acidos carboxilicos biologicamente activos.
US4923901A (en) 1987-09-04 1990-05-08 Millipore Corporation Membranes with bound oligonucleotides and peptides
US5175273A (en) 1988-07-01 1992-12-29 Genentech, Inc. Nucleic acid intercalating agents
US4943629A (en) 1988-08-12 1990-07-24 American Cyanamid Company Antidiabetic alpha-substituted phosphonates
US4945158A (en) 1988-08-12 1990-07-31 American Cyanamid Company Antidiabetic phosphonates
US5262530A (en) 1988-12-21 1993-11-16 Applied Biosystems, Inc. Automated system for polynucleotide synthesis and purification
US5047524A (en) 1988-12-21 1991-09-10 Applied Biosystems, Inc. Automated system for polynucleotide synthesis and purification
JP2794461B2 (ja) 1989-08-17 1998-09-03 有機合成薬品工業株式会社 ホスホアミダイト化合物及びそれを用いたオリゴリボヌクレオチドの固相合成法
US5141813A (en) 1989-08-28 1992-08-25 Clontech Laboratories, Inc. Multifunctional controlled pore glass reagent for solid phase oligonucleotide synthesis
US5134066A (en) 1989-08-29 1992-07-28 Monsanto Company Improved probes using nucleosides containing 3-dezauracil analogs
CA2029273A1 (en) 1989-12-04 1991-06-05 Christine L. Brakel Modified nucleotide compounds
US5130302A (en) 1989-12-20 1992-07-14 Boron Bilogicals, Inc. Boronated nucleoside, nucleotide and oligonucleotide compounds, compositions and methods for using same
EP0507863A4 (en) 1989-12-28 1993-07-07 Virginia Commonwealth University Sigma receptor ligands and the use thereof
US5587361A (en) 1991-10-15 1996-12-24 Isis Pharmaceuticals, Inc. Oligonucleotides having phosphorothioate linkages of high chiral purity
US5506212A (en) 1990-01-11 1996-04-09 Isis Pharmaceuticals, Inc. Oligonucleotides with substantially chirally pure phosphorothioate linkages
US6339066B1 (en) 1990-01-11 2002-01-15 Isis Pharmaceuticals, Inc. Antisense oligonucleotides which have phosphorothioate linkages of high chiral purity and which modulate βI, βII, γ, δ, Ε, ζ and η isoforms of human protein kinase C
US7101993B1 (en) 1990-01-11 2006-09-05 Isis Pharmaceuticals, Inc. Oligonucleotides containing 2′-O-modified purines
US5681941A (en) 1990-01-11 1997-10-28 Isis Pharmaceuticals, Inc. Substituted purines and oligonucleotide cross-linking
US5646265A (en) 1990-01-11 1997-07-08 Isis Pharmceuticals, Inc. Process for the preparation of 2'-O-alkyl purine phosphoramidites
US5459255A (en) 1990-01-11 1995-10-17 Isis Pharmaceuticals, Inc. N-2 substituted purines
US5587470A (en) 1990-01-11 1996-12-24 Isis Pharmaceuticals, Inc. 3-deazapurines
US5852188A (en) 1990-01-11 1998-12-22 Isis Pharmaceuticals, Inc. Oligonucleotides having chiral phosphorus linkages
US5914396A (en) 1990-01-11 1999-06-22 Isis Pharmaceuticals, Inc. 2'-O-modified nucleosides and phosphoramidites
WO1991010671A1 (en) 1990-01-11 1991-07-25 Isis Pharmaceuticals, Inc. Compositions and methods for detecting and modulating rna activity and gene expression
US5620963A (en) 1991-10-15 1997-04-15 Isis Pharmaceuticals, Inc. Oligonucleotides for modulating protein kinase C having phosphorothioate linkages of high chiral purity
US5635488A (en) 1991-10-15 1997-06-03 Isis Pharmaceuticals, Inc. Compounds having phosphorodithioate linkages of high chiral purity
US5457191A (en) 1990-01-11 1995-10-10 Isis Pharmaceuticals, Inc. 3-deazapurines
US5212295A (en) 1990-01-11 1993-05-18 Isis Pharmaceuticals Monomers for preparation of oligonucleotides having chiral phosphorus linkages
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
US5292875A (en) 1990-04-20 1994-03-08 Lynx Therapeutics, Inc. Method of synthesizing sulfurized oligonucleotide analogs
ES2139578T3 (es) 1990-05-23 2000-02-16 Isis Pharmaceuticals Inc Composiciones y procedimiento para modular la actividad del arn mediante la modificacion de la estructura protectora 5' del arn.
US5602240A (en) 1990-07-27 1997-02-11 Ciba Geigy Ag. Backbone modified oligonucleotide analogs
WO1994022886A1 (en) 1993-03-30 1994-10-13 Isis Pharmaceuticals, Inc. Heteroatomic oligonucleoside linkages
US5998603A (en) 1994-09-29 1999-12-07 Isis Pharmaceuticals, Inc. 4'-desmethyl nucleoside analogs, and oligomers thereof
US5223618A (en) 1990-08-13 1993-06-29 Isis Pharmaceuticals, Inc. 4'-desmethyl nucleoside analog compounds
US5608046A (en) 1990-07-27 1997-03-04 Isis Pharmaceuticals, Inc. Conjugated 4'-desmethyl nucleoside analog compounds
US5610289A (en) 1990-07-27 1997-03-11 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogues
US5792844A (en) 1990-07-27 1998-08-11 Isis Pharmaceuticals, Inc. Oligonucleoside linkages containing adjacent nitrogen atoms
US5834607A (en) 1990-07-27 1998-11-10 Isis Pharmaceuticals, Inc. Amines and methods of making and using the same
US5783682A (en) 1990-07-27 1998-07-21 Isis Pharmaceuticals, Inc. Oligonucleotide mimics having nitrogen-containing linkages
US5489677A (en) 1990-07-27 1996-02-06 Isis Pharmaceuticals, Inc. Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms
CA2088258C (en) 1990-07-27 2004-09-14 Phillip Dan Cook Nuclease resistant, pyrimidine modified oligonucleotides that detect and modulate gene expression
US6121433A (en) 1990-07-27 2000-09-19 Isis Pharmaceuticals, Inc. Oligomeric compounds having nitrogen-containing linkages
US5618704A (en) 1990-07-27 1997-04-08 Isis Pharmacueticals, Inc. Backbone-modified oligonucleotide analogs and preparation thereof through radical coupling
US5677437A (en) 1990-07-27 1997-10-14 Isis Pharmaceuticals, Inc. Heteroatomic oligonucleoside linkages
US5688941A (en) 1990-07-27 1997-11-18 Isis Pharmaceuticals, Inc. Methods of making conjugated 4' desmethyl nucleoside analog compounds
US5138045A (en) 1990-07-27 1992-08-11 Isis Pharmaceuticals Polyamine conjugated oligonucleotides
US5623070A (en) 1990-07-27 1997-04-22 Isis Pharmaceuticals, Inc. Heteroatomic oligonucleoside linkages
US5386023A (en) 1990-07-27 1995-01-31 Isis Pharmaceuticals Backbone modified oligonucleotide analogs and preparation thereof through reductive coupling
US5378825A (en) 1990-07-27 1995-01-03 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs
US5541307A (en) 1990-07-27 1996-07-30 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs and solid phase synthesis thereof
US6087482A (en) 1990-07-27 2000-07-11 Isis Pharmaceuticals, Inc. Heteroatomic oligonucleoside linkages
US5432272A (en) 1990-10-09 1995-07-11 Benner; Steven A. Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
JPH04348044A (ja) 1991-02-21 1992-12-03 Matsushita Electron Corp 半導体用樹脂封止装置
US5512668A (en) 1991-03-06 1996-04-30 Polish Academy Of Sciences Solid phase oligonucleotide synthesis using phospholane intermediates
US7015315B1 (en) 1991-12-24 2006-03-21 Isis Pharmaceuticals, Inc. Gapped oligonucleotides
US20020183502A1 (en) 1991-05-21 2002-12-05 Mesmaeker Alain De Backbone-modified oligonucleotide analogs and methods for using same
JPH04348077A (ja) 1991-05-24 1992-12-03 Nec Corp 薄膜トランジスタ
US6414112B1 (en) 1991-05-24 2002-07-02 Ole Buchardt Peptide nucleic acids having 2,6-diaminopurine nucleobases
CA2111108A1 (en) 1991-06-10 1992-12-23 Joong Myung Cho Hepatitis c diagnostics and vaccines
US5359052A (en) 1991-08-05 1994-10-25 Polish Academy Of Sciences Chalcophospholanes useful in the synthesis of oligonucleoside phosphorothioates, phosphorodithioates and related selenates
US5646267A (en) 1991-08-05 1997-07-08 Polish Academy Of Sciences Method of making oligonucleotides and oligonucleotide analogs using phospholanes and enantiomerically resolved phospholane analogues
US7119184B2 (en) 1991-08-12 2006-10-10 Isis Pharmaceuticals, Inc. Oligonucleotides having A-DNA form and B-DNA form conformational geometry
US6369209B1 (en) 1999-05-03 2002-04-09 Isis Pharmaceuticals, Inc. Oligonucleotides having A-DNA form and B-DNA form conformational geometry
US5661134A (en) 1991-10-15 1997-08-26 Isis Pharmaceuticals, Inc. Oligonucleotides for modulating Ha-ras or Ki-ras having phosphorothioate linkages of high chiral purity
US5599797A (en) 1991-10-15 1997-02-04 Isis Pharmaceuticals, Inc. Oligonucleotides having phosphorothioate linkages of high chiral purity
US5607923A (en) 1991-10-15 1997-03-04 Isis Pharmaceuticals, Inc. Oligonucleotides for modulating cytomegalovirus having phosphorothioate linkages of high chiral purity
EP0655088B1 (en) 1991-10-15 2002-07-24 Isis Pharmaceuticals, Inc. Oligonucleotides having chiral phosphorus linkages
US5654284A (en) 1991-10-15 1997-08-05 Isis Pharmaceuticals, Inc. Oligonucleotides for modulating RAF kinase having phosphorothioate linkages of high chiral purity
US5576302A (en) 1991-10-15 1996-11-19 Isis Pharmaceuticals, Inc. Oligonucleotides for modulating hepatitis C virus having phosphorothioate linkages of high chiral purity
ES2103918T3 (es) 1991-10-17 1997-10-01 Ciba Geigy Ag Nucleosidos biciclicos, oligonucleotidos, procedimiento para su obtencion y productos intermedios.
US5594121A (en) 1991-11-07 1997-01-14 Gilead Sciences, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified purines
US5484908A (en) 1991-11-26 1996-01-16 Gilead Sciences, Inc. Oligonucleotides containing 5-propynyl pyrimidines
US6235887B1 (en) 1991-11-26 2001-05-22 Isis Pharmaceuticals, Inc. Enhanced triple-helix and double-helix formation directed by oligonucleotides containing modified pyrimidines
US5359044A (en) 1991-12-13 1994-10-25 Isis Pharmaceuticals Cyclobutyl oligonucleotide surrogates
DK0618925T4 (da) 1991-12-24 2012-07-09 Isis Pharmaceuticals Inc Antisense-oligonukleotider
GB9213601D0 (en) 1992-06-26 1992-08-12 Mastico Robert A Protein based delivery system
US7067497B2 (en) 1992-09-29 2006-06-27 Isis Pharmaceuticals, Inc. Modulation of telomere length by oligonucleotides having a G-core sequence
US6005107A (en) 1992-12-23 1999-12-21 Biochem Pharma, Inc. Antiviral compounds
US6444656B1 (en) 1992-12-23 2002-09-03 Biochem Pharma, Inc. Antiviral phosphonate nucleotides
ATE138384T1 (de) 1993-01-25 1996-06-15 Hybridon Inc Olionukleotidalkylphosphonate und - phosphonothioate
CA2159632A1 (en) 1993-03-31 1994-10-13 Ashis Kumar Saha Novel 5'-substituted nucleosides and oligomers produced therefrom
AU6551094A (en) 1993-03-31 1994-10-24 Sterling Winthrop Inc. Bifunctional nucleosides, oligomers thereof, and methods of making and using the same
US5955591A (en) * 1993-05-12 1999-09-21 Imbach; Jean-Louis Phosphotriester oligonucleotides, amidites and method of preparation
US6015886A (en) 1993-05-24 2000-01-18 Chemgenes Corporation Oligonucleotide phosphate esters
DE69412704T2 (de) 1993-06-10 1999-02-04 Idemitsu Petrochemical Co., Ltd., Tokio/Tokyo Spritzgiessform
US5502177A (en) 1993-09-17 1996-03-26 Gilead Sciences, Inc. Pyrimidine derivatives for labeled binding partners
US5643989A (en) 1993-10-29 1997-07-01 Azdel, Inc. Fiber reinforced functionalized polyolefin composites
WO1998003542A1 (en) 1996-07-24 1998-01-29 Buchardt, Dorte Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
US5457187A (en) 1993-12-08 1995-10-10 Board Of Regents University Of Nebraska Oligonucleotides containing 5-fluorouracil
DE4435728A1 (de) 1994-01-19 1995-07-20 Boehringer Mannheim Gmbh Biotinsilan-Verbindungen und diese Verbindungen enthaltende Bindematrix
US6117679A (en) 1994-02-17 2000-09-12 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
CN1077598C (zh) 1994-02-22 2002-01-09 诺沃奇梅兹有限公司 制备脂解酶变异体的方法
US5596091A (en) 1994-03-18 1997-01-21 The Regents Of The University Of California Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
AU2445795A (en) 1994-05-11 1995-12-05 Novo Nordisk A/S An enzyme with endo-1,3(4)-beta -glucanase activity
US5525711A (en) 1994-05-18 1996-06-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pteridine nucleotide analogs as fluorescent DNA probes
HRP950288A2 (en) 1994-05-31 1997-08-31 Bayer Ag Oxalylamino-benzofuran- and benzothienyl-derivatives
ATE175667T1 (de) 1994-05-31 1999-01-15 Bayer Ag Aminobenzofuryl- und -thienylderivate
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
JP3468773B2 (ja) 1994-07-15 2003-11-17 ザ ユニバーシティ オブ アイオワ リサーチ ファウンデーション 免疫調節オリゴヌクレオチド
JPH10505094A (ja) * 1994-09-07 1998-05-19 ハイブリドン・インコーポレイテッド オリゴヌクレオチドプロドラッグ
US5681940A (en) 1994-11-02 1997-10-28 Icn Pharmaceuticals Sugar modified nucleosides and oligonucleotides
AU4514696A (en) 1994-12-22 1996-07-10 Hybridon, Inc. Synthesis of stereospecific oligonucleotide phosphorothioates
GB9501465D0 (en) 1995-01-25 1995-03-15 King S College London Nucleoside phosphorothioate derivatives,synthesis and use thereof
US6166197A (en) 1995-03-06 2000-12-26 Isis Pharmaceuticals, Inc. Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions
ATE327244T1 (de) 1995-03-06 2006-06-15 Isis Pharmaceuticals Inc Verfahren zur synthese von 2'-0-substituierten pyrimidinen und oligomere davon
DE69638104D1 (de) 1995-04-27 2010-02-11 Takara Bio Inc Für Lacto-N-biosidase kodierendes Gen
RU2205874C2 (ru) 1995-05-11 2003-06-10 Апплайд Резеч Системз Арс Холдинг Н.В. Нуклеотидная последовательность, способная ингибировать активность il-6, плазмидный вектор для трансфекции в клетки млекопитающих, нуклеотидная последовательность, используемая при терапии, фармацевтическая композиция (варианты)
WO1996036627A1 (en) 1995-05-19 1996-11-21 Glycomed Incorporated Collection of activated glycoside compounds and their biological use
DE69609511T2 (de) 1995-05-23 2001-03-29 Hybridon, Inc. Neue Synthons für die stereoselektive Oligonuklodsynthese
AU5871196A (en) 1995-05-23 1996-12-24 Hybridon, Inc. Methods and compounds for the synthesis of oligonucleotides and the oligonucleotides thereby produced
JPH10510433A (ja) 1995-06-06 1998-10-13 アイシス・ファーマシューティカルス・インコーポレーテッド 高いキラル純度のホスホロチオエート結合を有するオリゴヌクレオチド
US5932450A (en) 1995-06-07 1999-08-03 Gen-Probe Incorporated Enzymatic synthesis of oligonucleotides using digestible templates
DE69635849T2 (de) 1995-06-29 2006-10-19 Takara Bio Inc., Otsu Für Endoglycoceramidase kodierendes Gen
EP0759470B1 (en) 1995-06-29 2006-10-25 Takara Bio Inc. Gene encoding endoglycoceramidase activator
US6017700A (en) 1995-08-04 2000-01-25 Bayer Corporation Cationic oligonucleotides, and related methods of synthesis and use
US5936080A (en) 1996-05-24 1999-08-10 Genta Incorporated Compositions and methods for the synthesis of organophosphorus derivatives
WO1997009443A1 (en) 1995-09-05 1997-03-13 Michigan State University PROCESS FOR THE ISOLATION AND PURIFICATION OF TAXOL AND TAXANES FROM TAXUS spp
US5734041A (en) 1995-10-20 1998-03-31 Mcgill University Preparation of chiral phosphorothioate oligomers
US6160109A (en) 1995-10-20 2000-12-12 Isis Pharmaceuticals, Inc. Preparation of phosphorothioate and boranophosphate oligomers
US6476216B1 (en) 1995-10-20 2002-11-05 Mcgill University Preparation of phosphorothioate oligomers
US7018793B1 (en) 1995-12-07 2006-03-28 Diversa Corporation Combinatorial screening of mixed populations of organisms
US6214805B1 (en) 1996-02-15 2001-04-10 The United States Of America As Represented By The Department Of Health And Human Services RNase L activators and antisense oligonucleotides effective to treat RSV infections
US5998602A (en) 1996-02-15 1999-12-07 The Cleveland Clinic Fouindation And Government RNase L activators and antisense oligonucleotides effective to treat RSV infections
GB9604669D0 (en) 1996-03-05 1996-05-01 Ciba Geigy Ag Chemical compounds
US5824669A (en) 1996-03-22 1998-10-20 Nitromed, Inc. Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders
WO1997043409A2 (en) 1996-05-10 1997-11-20 Novo Nordisk A/S Method of providing novel dna sequences
US5856465A (en) 1996-05-24 1999-01-05 Polska Akademia Nauk Centrum Badan Molekularnych I Makromolekularnych Compositions and methods for the synthesis of chirally pure organophosphorus nucleoside derivatives
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
DE19622783A1 (de) 1996-06-07 1997-12-11 Hoechst Ag Isolierung der Biosynthesegene für Pseudo-Oligosaccharide aus Streptomyces glaucescens GLA.O und ihre Verwendung
DK0912767T3 (da) 1996-07-16 2006-10-30 Gen Probe Inc Fremgangsmåde til sporing og forstærkning af nukleinsyresekvenser ved anvendelse af modificerede oligonukleotider med foröget targetspecifikt TM
AU4156197A (en) * 1996-08-21 1998-03-06 Hybridon, Inc. Oligonucleotide prodrugs
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
GB9621522D0 (en) 1996-10-16 1996-12-04 Biocompatibles Ltd Synthesis of phosphorus compounds
US6172209B1 (en) 1997-02-14 2001-01-09 Isis Pharmaceuticals Inc. Aminooxy-modified oligonucleotides and methods for making same
US6639062B2 (en) 1997-02-14 2003-10-28 Isis Pharmaceuticals, Inc. Aminooxy-modified nucleosidic compounds and oligomeric compounds prepared therefrom
US6369237B1 (en) 1997-03-07 2002-04-09 President And Fellows Of Harvard College DNA glycosylase inhibitors, and uses related thereto
US6015887A (en) 1997-04-11 2000-01-18 Isis Pharmaceuticals, Inc. Chiral peptide nucleic acids and methods for preparing same
US6468983B2 (en) 1997-04-21 2002-10-22 The Cleveland Clinic Foundation RNase L activators and antisense oligonucleotides effective to treat telomerase-expressing malignancies
PL184612B1 (pl) 1997-04-25 2002-11-29 Pan Sposób wytwarzania modyfikowanych P chiralnych analogów nukleotydów
JP2001501975A (ja) 1997-05-28 2001-02-13 ペーター・エー・ニールセン 亢進した細胞取り込みを有する結合ペプチド核酸
JP2002507212A (ja) 1997-06-27 2002-03-05 ザ、プロクター、エンド、ギャンブル、カンパニー プロ芳香性環状アセタール
WO1999005160A2 (en) 1997-07-25 1999-02-04 Hybridon, Inc. Oligonuclotides having 3' terminal stereospecific phosphorothioates
US6767739B2 (en) 2001-07-30 2004-07-27 Isis Pharmaceuticals Inc. Antisense modulation of microsomal triglyceride transfer protein expression
US6383808B1 (en) 2000-09-11 2002-05-07 Isis Pharmaceuticals, Inc. Antisense inhibition of clusterin expression
GB9717158D0 (en) 1997-08-13 1997-10-22 King S College London Solution synthesis of oligonucleotides and their phosphorothioate analogues
US6750344B1 (en) 1997-09-05 2004-06-15 Isis Pharmaceuticals, Inc. Amine compounds and combinatorial libraries comprising same
US6794499B2 (en) 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
DE19741715A1 (de) 1997-09-22 1999-03-25 Hoechst Ag Pentopyranosyl-Nucleosid, seine Herstellung und Verwendung
US6232463B1 (en) 1997-10-09 2001-05-15 Isis Pharmaceuticals, Inc. Substituted purines and oligonucleotide cross-linking
US6528640B1 (en) 1997-11-05 2003-03-04 Ribozyme Pharmaceuticals, Incorporated Synthetic ribonucleic acids with RNAse activity
US6617438B1 (en) 1997-11-05 2003-09-09 Sirna Therapeutics, Inc. Oligoribonucleotides with enzymatic activity
US6080543A (en) 1997-12-08 2000-06-27 E. & J. Gallo Winery Detection of fungal pathogens
US6582936B1 (en) 1997-12-12 2003-06-24 The Regents Of The University Of California Methods for making nucleic acids
US6248519B1 (en) 1998-03-11 2001-06-19 E & J Gallo Winery Detection of fermentation-related microorganisms
US7045610B2 (en) 1998-04-03 2006-05-16 Epoch Biosciences, Inc. Modified oligonucleotides for mismatch discrimination
JP2002513763A (ja) 1998-05-06 2002-05-14 ユニバーシティ オブ アイオワ リサーチ ファウンデーション Cpgオリゴヌクレオチドを使用して寄生生物感染および関連する疾患を予防および処置するための方法
NZ508650A (en) 1998-05-14 2003-05-30 Coley Pharm Gmbh Regulating hematopoiesis using unmethylated C and G CpG-oligonucleotides with a phosphorothioate modification
US6242589B1 (en) 1998-07-14 2001-06-05 Isis Pharmaceuticals, Inc. Phosphorothioate oligonucleotides having modified internucleoside linkages
US6867294B1 (en) 1998-07-14 2005-03-15 Isis Pharmaceuticals, Inc. Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages
JP2002521489A (ja) 1998-07-27 2002-07-16 ユニバーシティ オブ アイオワ リサーチ ファウンデーション CpGオリゴヌクレオチドの立体異性体および関連する方法
ATE315405T1 (de) 1998-08-10 2006-02-15 Antigenics Inc Cpg-zusammensetzungen, saponin-adjuvantien und verfahren zu deren verwendung
WO2000023444A1 (en) 1998-10-21 2000-04-27 Abbott Laboratories 5,7-disubstituted-4-aminopyrido[2,3-d]pyrimidine compounds
US6995259B1 (en) 1998-10-23 2006-02-07 Sirna Therapeutics, Inc. Method for the chemical synthesis of oligonucleotides
US6451524B1 (en) 1998-11-25 2002-09-17 Isis Pharmaceuticals, Inc. Identification of disease predictive nucleic acids
WO2000031110A1 (en) 1998-11-25 2000-06-02 Isis Pharmaceuticals, Inc. Identification of disease predictive nucleic acids
DE69941223D1 (de) 1998-12-21 2009-09-17 Billig Fritz Chemisch modifizierte enzymen mit mehrfachgeladenen varianten
CA2359816C (en) 1999-01-06 2010-08-03 Genenews Inc. Method for the detection of gene transcripts in blood and uses thereof
US6265172B1 (en) 1999-02-08 2001-07-24 University Of Kentucky Diagnostic test and therapy for manganese superoxide dismutate (mNsod) associated diseases
US6121437A (en) 1999-03-16 2000-09-19 Isis Pharmaceuticals, Inc. Phosphate and thiophosphate protecting groups
US6506594B1 (en) 1999-03-19 2003-01-14 Cornell Res Foundation Inc Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays
GB9907245D0 (en) 1999-03-29 1999-05-26 Goldsborough Andrew Cleavage of nucleic acids from solid supports
JP3072345B1 (ja) 1999-03-31 2000-07-31 農林水産省家畜衛生試験場長 豚丹毒菌の組換えサブユニットワクチン
US5998148A (en) 1999-04-08 1999-12-07 Isis Pharmaceuticals Inc. Antisense modulation of microtubule-associated protein 4 expression
US6977245B2 (en) 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
US6300069B1 (en) 1999-05-03 2001-10-09 Qiagen Gmbh Generation and amplification of nucleic acids from ribonucleic acids
US6656730B1 (en) 1999-06-15 2003-12-02 Isis Pharmaceuticals, Inc. Oligonucleotides conjugated to protein-binding drugs
US6271004B1 (en) 1999-06-25 2001-08-07 Display Systems Biotech A/S Method for improved reverse transcription at high temperatures
US6066500A (en) 1999-06-25 2000-05-23 Isis Pharmaceuticals Inc. Antisense modulation of Beta catenin expression
US6414135B1 (en) 1999-07-07 2002-07-02 Isis Pharmaceuticals, Inc. C3′-methylene hydrogen phosphonate monomers and related compounds
US20030092647A1 (en) 2001-08-08 2003-05-15 Crooke Rosanne M. Antisense modulation of cholesteryl ester transfer protein expression
US6147200A (en) 1999-08-19 2000-11-14 Isis Pharmaceuticals, Inc. 2'-O-acetamido modified monomers and oligomers
US7264932B2 (en) 1999-09-24 2007-09-04 Applera Corporation Nuclease inhibitor cocktail
EP1700603A3 (en) 1999-09-25 2007-06-13 Coley Pharmaceutical GmbH Immunostimulatory nucleic acids
MXPA02003059A (es) 1999-09-27 2002-09-30 Univ Iowa Res Found Metodos relacionados con interferon inducido por acido nucleico inmunoestabilizador.
US6949520B1 (en) 1999-09-27 2005-09-27 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon
US20020082227A1 (en) 1999-09-30 2002-06-27 Scott Henry Use of oligonucleotides for inhibition of complement activation
IL148922A0 (en) 1999-10-06 2002-09-12 Quark Biotech Inc Method for enrichment of natural antisense messenger rna
GB9924285D0 (en) 1999-10-14 1999-12-15 Avecia Ltd Process
US20010055761A1 (en) 1999-10-29 2001-12-27 Agilent Technologies Small scale dna synthesis using polymeric solid support with functionalized regions
FR2800750B1 (fr) 1999-11-05 2003-01-31 Centre Nat Rech Scient Proteines membranaires ctl (choline transporter like) impliquees dans le transport de la choline
AU1656601A (en) 1999-11-12 2001-06-12 Isis Pharmaceuticals, Inc. Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages
US6322985B1 (en) 1999-12-27 2001-11-27 Technion Research And Development Foundation Ltd. Abundant, well distributed and hyperpolymorphic simple sequence repeats in prokaryote genomes and use of same for prokaryote classification and typing
US7501091B2 (en) 1999-12-30 2009-03-10 Smiths Detection Inc. Sensors with improved properties
US7055094B2 (en) 1999-12-30 2006-05-30 Rutgers, The State University Of New Jersey Virtual tags and the process of virtual tagging utilizing user feedback in transformation rules
US6649750B1 (en) 2000-01-05 2003-11-18 Isis Pharmaceuticals, Inc. Process for the preparation of oligonucleotide compounds
US6159697A (en) 2000-01-19 2000-12-12 Isis Pharmaceuticals, Inc. Antisense modulation of Smad7 expression
US7585847B2 (en) 2000-02-03 2009-09-08 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for the treatment of asthma and allergy
US6495677B1 (en) 2000-02-15 2002-12-17 Kanda S. Ramasamy Nucleoside compounds
GB0004889D0 (en) 2000-03-01 2000-04-19 Avecia Ltd Synthesis of oligonucleotides
CA2335389A1 (en) 2000-03-01 2001-09-01 Message Pharmaceuticals, Inc. Novel bacterial rnase p proteins and their use in identifying antibacterial compounds
EP1265840A2 (en) 2000-03-17 2002-12-18 Corixa Corporation Novel amphipathic aldehydes and their use as adjuvants and immunoeffectors
WO2001081303A1 (en) 2000-04-20 2001-11-01 F. Hoffmann-La Roche Ag Pyrrolidine and piperidine derivatives and their use for the treament of neurodegenerative disorders
DE10019756A1 (de) 2000-04-20 2001-10-25 Bayer Ag Verfahren zur Herstellung von superabsorbierenden Polymeren aus Polyacrylnitrilen
US20020013287A1 (en) 2000-05-09 2002-01-31 Reliable Biopharmaceuticals, Inc. St Louis Missouri Polymeric compounds useful as prodrugs
US6492171B2 (en) 2000-05-16 2002-12-10 Isis Pharmaceuticals, Inc. Antisense modulation of TERT expression
US6815542B2 (en) 2000-06-16 2004-11-09 Ribapharm, Inc. Nucleoside compounds and uses thereof
EP1307469B1 (en) 2000-08-03 2008-01-23 Boehringer Mannheim Gmbh Nucleic acid binding compounds containing pyrazolo¬3,4-d pyrimidine analogues of purin-2,6-diamine and their uses
US6725412B1 (en) 2000-08-15 2004-04-20 Dolby Laboratories Licensing Corporation Low latency data encoder
US6809195B1 (en) 2000-08-16 2004-10-26 Isis Pharmaceuticals, Inc. Process for the preparation of oligonucleotides
US6559279B1 (en) 2000-09-08 2003-05-06 Isis Pharmaceuticals, Inc. Process for preparing peptide derivatized oligomeric compounds
ATE510850T1 (de) 2000-09-15 2011-06-15 Coley Pharm Gmbh Verfahren zum hochdurchsatzscreening von auf cpg basierenden immunagonisten und -antagonisten
EP1191097A1 (en) 2000-09-21 2002-03-27 Leids Universitair Medisch Centrum Induction of exon skipping in eukaryotic cells
GB0024752D0 (en) 2000-10-10 2000-11-22 Univ Belfast Oxidative halogenation of aromatic compounds
EP1889630B1 (en) 2000-10-18 2011-11-23 GlaxoSmithKline Biologicals S.A. Vaccines comprising MAGE antigen linked to protein D fragment
US6372492B1 (en) 2000-10-30 2002-04-16 Isis Pharmaceuticals, Inc. Antisense modulation of talin expression
US6682889B1 (en) 2000-11-08 2004-01-27 Becton, Dickinson And Company Amplification and detection of organisms of the Chlamydiaceae family
NL1016978C2 (nl) 2000-12-22 2002-06-25 Robert Jan Colenbrander Inrichting en werkwijze voor het verpakken en bereiden van voedsel en werkwijze voor het vervaardigen van een dergelijke inrichting.
EP1355916B1 (en) 2001-01-22 2007-01-10 Merck & Co., Inc. Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
US8008459B2 (en) 2001-01-25 2011-08-30 Evolva Sa Concatemers of differentially expressed multiple genes
CA2474172C (en) 2001-01-25 2012-07-10 Evolva Ltd. A library of a collection of cells
JP4454934B2 (ja) 2001-01-26 2010-04-21 コモンウェルス サイエンティフィック アンド インダストリアル リサーチ オーガニゼイション 組換えクローニングを用いて効率のよいサイレンシング構築物を作製する方法および手段
US20050277133A1 (en) 2001-05-18 2005-12-15 Sirna Therapeutics, Inc. RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA)
WO2002097134A2 (en) 2001-05-25 2002-12-05 Isis Pharmaceuticals, Inc. Modified peptide nucleic acid
GB0113523D0 (en) 2001-06-04 2001-07-25 Torotrak Dev Ltd An Hydraulic control circuit for a continuosly variable transmission
US20030069410A1 (en) 2001-06-14 2003-04-10 Isis Pharmaceuticals, Inc. Methods for preparing oligonucleotides having chiral phosphorothioate linkages
US20050019915A1 (en) 2001-06-21 2005-01-27 Bennett C. Frank Antisense modulation of superoxide dismutase 1, soluble expression
RU2316347C2 (ru) 2001-06-29 2008-02-10 Чирон Корпорейшн Композиция для стимуляции иммунного ответа (варианты), способы ее получения, применения и способы стимуляции иммунного ответа с использованием этих композиций
WO2003004602A2 (en) 2001-07-03 2003-01-16 Isis Pharmaceuticals, Inc. Nuclease resistant chimeric oligonucleotides
US7205399B1 (en) 2001-07-06 2007-04-17 Sirna Therapeutics, Inc. Methods and reagents for oligonucleotide synthesis
US6440739B1 (en) 2001-07-17 2002-08-27 Isis Pharmaceuticals, Inc. Antisense modulation of glioma-associated oncogene-2 expression
US7425545B2 (en) 2001-07-25 2008-09-16 Isis Pharmaceuticals, Inc. Modulation of C-reactive protein expression
US7407943B2 (en) 2001-08-01 2008-08-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein B expression
US6455308B1 (en) 2001-08-01 2002-09-24 Isis Pharmaceuticals, Inc. Antisense modulation of serum amyloid A4 expression
US7888324B2 (en) 2001-08-01 2011-02-15 Genzyme Corporation Antisense modulation of apolipoprotein B expression
US7227014B2 (en) 2001-08-07 2007-06-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein (a) expression
US7259150B2 (en) 2001-08-07 2007-08-21 Isis Pharmaceuticals, Inc. Modulation of apolipoprotein (a) expression
AU2002361468A1 (en) 2001-08-14 2003-03-18 The Government Of The United States Of America As Represented By The Secretary Of Health And Human S Method for rapid generation of mature dendritic cells
EP1418877A2 (en) 2001-08-24 2004-05-19 Massachusetts Institute Of Technology Reagents that facilitate the purification of compounds synthesized on a solid support
US7049122B2 (en) 2001-09-21 2006-05-23 Academia Sinica Mutant-type lipases and applications thereof
US6933288B2 (en) 2002-02-04 2005-08-23 Isis Pharmaceuticals, Inc. Pyranosyl cytosines: pharmaceutical formulations and methods
JP4348044B2 (ja) 2002-02-12 2009-10-21 株式会社キラルジェン 立体規則性の高いジヌクレオシドホスホロチオエートの製造法
US20030159938A1 (en) 2002-02-15 2003-08-28 George Hradil Electroplating solution containing organic acid complexing agent
US20040149587A1 (en) 2002-02-15 2004-08-05 George Hradil Electroplating solution containing organic acid complexing agent
US8232383B2 (en) 2002-02-20 2012-07-31 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US20050096284A1 (en) 2002-02-20 2005-05-05 Sirna Therapeutics, Inc. RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA)
EP1485396A2 (en) 2002-02-28 2004-12-15 Biota, Inc. Nucleoside 5'-monophosphate mimics and their prodrugs
WO2003072757A2 (en) 2002-02-28 2003-09-04 Biota, Inc. Nucleotide mimics and their prodrugs
US7288376B2 (en) 2002-03-22 2007-10-30 Council Of Scientific And Industrial Research Method of detection of SP-A2 gene variants useful for prediction of predisposition to aspergillosis
US20040102394A1 (en) 2002-11-23 2004-05-27 Isis Pharmaceuticals Inc. Modulation of huntingtin interacting protein 2 expression
US7247621B2 (en) 2002-04-30 2007-07-24 Valeant Research & Development Antiviral phosphonate compounds and methods therefor
AU2003237875A1 (en) 2002-05-15 2003-12-02 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein b expression
AU2003241621A1 (en) 2002-05-24 2003-12-12 Isis Pharmaceuticals, Inc. Oligonucleotides having modified nucleoside units
US20040014957A1 (en) 2002-05-24 2004-01-22 Anne Eldrup Oligonucleotides having modified nucleoside units
US7507808B2 (en) 2002-12-12 2009-03-24 Isis Pharmaceuticals, Inc. Modulation of endothelial lipase expression
AU2003248708A1 (en) 2002-06-17 2003-12-31 Isis Pharmaceuticals, Inc. Oligomeric compounds that include carbocyclic nucleosides and their use in gene modulation
WO2004000351A1 (en) 2002-06-20 2003-12-31 Cytos Biotechnology Ag Packaged virus-like particles for use as adjuvants: method of preparation and use
WO2004003228A1 (en) 2002-07-01 2004-01-08 Unisearch Limited Genotyping method
EP2333062A1 (en) 2002-07-10 2011-06-15 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. RNA-interference by single-stranded RNA molecules
US20040023905A1 (en) 2002-07-31 2004-02-05 Isis Pharmaceuticals Inc. Antisense modulation of LAR expression
US20080274989A1 (en) 2002-08-05 2008-11-06 University Of Iowa Research Foundation Rna Interference Suppression of Neurodegenerative Diseases and Methods of Use Thereof
US20050042646A1 (en) 2002-08-05 2005-02-24 Davidson Beverly L. RNA interference suppresion of neurodegenerative diseases and methods of use thereof
US20050255086A1 (en) 2002-08-05 2005-11-17 Davidson Beverly L Nucleic acid silencing of Huntington's Disease gene
WO2004014933A1 (en) 2002-08-07 2004-02-19 University Of Massachusetts Compositions for rna interference and methods of use thereof
AU2003259735A1 (en) 2002-08-08 2004-02-25 Sirna Therapeutics, Inc. Small-mer compositions and methods of use
AR040996A1 (es) 2002-08-19 2005-04-27 Coley Pharm Group Inc Acidos nucleicos inmunoestimuladores
US7414116B2 (en) 2002-08-23 2008-08-19 Illumina Cambridge Limited Labelled nucleotides
AU2003267785C1 (en) 2002-09-13 2009-12-24 Replicor, Inc. Non-sequence complementary antiviral oligonucleotides
US7030230B2 (en) 2002-10-25 2006-04-18 Isis Pharmaceuticals, Inc. Process of purifying phosphoramidites
AU2003283647B2 (en) 2002-10-29 2010-04-15 Coley Pharmaceutical Gmbh Use of CPG oligonucleotides in the treatment of hepatitis C virus infection
WO2004042018A2 (en) 2002-11-01 2004-05-21 The Regents Of The University Of Colorado Dopamine neurons from human embryonic stem cells
WO2004044139A2 (en) 2002-11-05 2004-05-27 Isis Parmaceuticals, Inc. Modified oligonucleotides for use in rna interference
AU2003291721A1 (en) 2002-11-05 2004-06-03 Isis Pharmaceuticals, Inc. Phosphorous-linked oligomeric compounds and their use in gene modulation
CA2505090A1 (en) 2002-11-05 2004-05-27 Isis Pharmaceuticals, Inc. Conjugated oligomeric compounds and their use in gene modulation
WO2004041889A2 (en) 2002-11-05 2004-05-21 Isis Pharmaceuticals, Inc. Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
US7381527B2 (en) 2002-11-06 2008-06-03 Council Of Scientific And Industrial Research Method of detection of SP-A2 gene variants
CA2505801A1 (en) 2002-11-13 2004-05-27 Rosanne Crooke Antisense modulation of apolipoprotein b expression
US7511131B2 (en) 2002-11-13 2009-03-31 Genzyme Corporation Antisense modulation of apolipoprotein B expression
EP2314691A3 (en) 2002-11-14 2012-01-18 Dharmacon, Inc. Fuctional and hyperfunctional siRNA
AU2003225705A1 (en) 2003-03-07 2004-09-30 Ribapharm Inc. Cytidine analogs and methods of use
ATE479752T1 (de) 2003-03-07 2010-09-15 Alnylam Pharmaceuticals Inc Therapeutische zusammensetzungen
CA2524255C (en) 2003-03-21 2014-02-11 Academisch Ziekenhuis Leiden Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
GB0306657D0 (en) 2003-03-24 2003-04-30 Avecia Ltd Process and compounds
US7537767B2 (en) 2003-03-26 2009-05-26 Cytis Biotechnology Ag Melan-A- carrier conjugates
AU2004223736B2 (en) 2003-03-26 2010-05-27 Cytos Biotechnology Ag Melan-A peptide analogue-virus-like-particle conjugates
ITRM20030149A1 (it) 2003-04-02 2004-10-03 Giuliani Spa Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
US7598227B2 (en) 2003-04-16 2009-10-06 Isis Pharmaceuticals Inc. Modulation of apolipoprotein C-III expression
US20050261237A1 (en) 2003-04-25 2005-11-24 Boojamra Constantine G Nucleoside phosphonate analogs
US20090247488A1 (en) 2003-04-25 2009-10-01 Carina Cannizzaro Anti-inflammatory phosphonate compounds
CN101410120A (zh) 2003-04-25 2009-04-15 吉里德科学公司 抗炎的膦酸酯化合物
DK1628685T3 (da) 2003-04-25 2011-03-21 Gilead Sciences Inc Antivirale phosphonatanaloge
WO2004096233A2 (en) 2003-04-25 2004-11-11 Gilead Sciences, Inc. Nucleoside phosphonate conjugates
KR20060061930A (ko) 2003-04-25 2006-06-08 길리애드 사이언시즈, 인코포레이티드 항암성 포스포네이트 유사체
US7432261B2 (en) 2003-04-25 2008-10-07 Gilead Sciences, Inc. Anti-inflammatory phosphonate compounds
WO2005002626A2 (en) 2003-04-25 2005-01-13 Gilead Sciences, Inc. Therapeutic phosphonate compounds
US7470724B2 (en) 2003-04-25 2008-12-30 Gilead Sciences, Inc. Phosphonate compounds having immuno-modulatory activity
US7452901B2 (en) 2003-04-25 2008-11-18 Gilead Sciences, Inc. Anti-cancer phosphonate analogs
US7407965B2 (en) 2003-04-25 2008-08-05 Gilead Sciences, Inc. Phosphonate analogs for treating metabolic diseases
US7045306B2 (en) 2003-04-28 2006-05-16 The General Hospital Corporation Method for identifying compounds in vitro that modulate the dysregulation of transcription of transcription mediated by mutant huntingtin protein
US7214491B2 (en) 2003-05-07 2007-05-08 E. I. Du Pont De Nemours And Company Δ-12 desaturase gene suitable for altering levels of polyunsaturated fatty acids in oleaginous yeasts
JP4179562B2 (ja) 2003-05-14 2008-11-12 独立行政法人科学技術振興機構 ハンチンチン遺伝子の発現抑制
EP1633307A4 (en) * 2003-06-03 2009-06-24 Isis Pharmaceuticals Inc MODULATION OF SURVIVIN EXPRESSION
BRPI0411514A (pt) 2003-06-20 2006-08-01 Coley Pharm Gmbh antagonistas de receptor toll-like de molécula pequena
EP2530157B1 (en) 2003-07-31 2016-09-28 Regulus Therapeutics Inc. Oligomeric compounds and compositions for use in modulation of miRNAs
JP2005089441A (ja) 2003-08-08 2005-04-07 Toudai Tlo Ltd 立体規則性の高いリン原子修飾ヌクレオチド類縁体の製造法
JP2011088935A (ja) 2003-08-08 2011-05-06 Chiralgen Ltd リン原子修飾ヌクレオチド類縁体の製造のための光学活性ヌクレオシド3’−ホスホロアミダイト
US7825235B2 (en) 2003-08-18 2010-11-02 Isis Pharmaceuticals, Inc. Modulation of diacylglycerol acyltransferase 2 expression
BRPI0413684A (pt) 2003-08-21 2006-10-24 Univ Griffith compostos, composição farmacêutica e respectivos métodos de preparação, de tratamento de infecção microbiana e de extermìnio de microrganismo e usos
BRPI0413682A (pt) 2003-08-21 2006-10-24 Univ Griffith compostos, composição farmacêutica e respectivos métodos de preparação, de tratamento de infecção microbiana e de extermìnio de microrganismo e usos
CN1863813B (zh) 2003-08-27 2011-03-30 生物区科学管理控股有限公司 作为治疗剂的三环核苷或核苷酸
JP4731324B2 (ja) 2003-08-28 2011-07-20 武 今西 N−o結合性架橋構造型新規人工核酸
JP4616175B2 (ja) 2003-09-02 2011-01-19 株式会社キラルジェン 5’−ホスフィチル化モノマーおよびh−ホスホネートオリゴヌクレオチド誘導体の製造方法
WO2005023828A1 (ja) 2003-09-02 2005-03-17 Takeshi Wada リボヌクレオチド又はリボヌクレオチド誘導体の製造方法
PT3342425T (pt) 2003-09-09 2020-03-05 Geron Corp Oligonucleótidos modificados por inibição da telomerase
US20050053981A1 (en) 2003-09-09 2005-03-10 Swayze Eric E. Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini
US20050074801A1 (en) 2003-09-09 2005-04-07 Monia Brett P. Chimeric oligomeric compounds comprising alternating regions of northern and southern conformational geometry
US8680063B2 (en) 2003-09-12 2014-03-25 University Of Massachusetts RNA interference for the treatment of gain-of-function disorders
WO2008005562A2 (en) 2006-07-07 2008-01-10 University Of Massachusetts Rna silencing compositions and methods for the treatment of huntington's disease
ES2969371T3 (es) 2003-09-12 2024-05-17 Univ Massachusetts Interferencia por ARN para el tratamiento de trastornos de ganancia de función
GB0323968D0 (en) 2003-10-13 2003-11-19 Glaxosmithkline Biolog Sa Immunogenic compositions
SG122973A1 (en) 2003-10-30 2006-06-29 Coley Pharm Gmbh C-class oligonucleotide analogs with enhanced immunostimulatory potency
US20050239102A1 (en) 2003-10-31 2005-10-27 Verdine Gregory L Nucleic acid binding oligonucleotides
US7846436B2 (en) * 2003-11-28 2010-12-07 Chemgenes Corporation Oligonucleotides and related compounds
WO2005063983A1 (en) 2003-12-29 2005-07-14 Galapagos Genomics N.V. Modulators of bone homeostasis identified in a high-throughput screen
WO2005070859A1 (ja) 2004-01-27 2005-08-04 Takeshi Wada フルオラス担体およびそれを用いたオリゴヌクレオチド誘導体の製造方法
US20050176045A1 (en) 2004-02-06 2005-08-11 Dharmacon, Inc. SNP discriminatory siRNA
US20080221303A1 (en) 2004-02-18 2008-09-11 Jehoshua Katzhendler Method for the Preparation of Peptide-Oligonucleotide Conjugates
JP3976742B2 (ja) 2004-02-27 2007-09-19 江守商事株式会社 インターフェロンアルファを誘導する免疫刺激オリゴヌクレオチド
WO2005085272A1 (ja) 2004-03-05 2005-09-15 Takeshi Wada ボラノホスフェートモノマーおよびそれを用いたオリゴヌクレオチド誘導体の製造方法
JP4865544B2 (ja) 2004-03-25 2012-02-01 株式会社キラルジェン 立体規則性の高いリボヌクレオチド類縁体及びデオキシリボヌクレオチド類縁体の製造法
WO2005097817A2 (en) 2004-04-05 2005-10-20 Alnylam Pharmaceuticals, Inc. Process and reagents for oligonucleotide synthesis and purification
US20050244869A1 (en) 2004-04-05 2005-11-03 Brown-Driver Vickie L Modulation of transthyretin expression
TWI350168B (en) 2004-05-07 2011-10-11 Incyte Corp Amido compounds and their use as pharmaceuticals
CA2572795A1 (en) 2004-05-27 2005-12-08 The Government Of The United States Of America As Represented By The Sec Retary Of The Department Of Health And Human Services Differential expression of molecules associated with acute stroke
US7759318B1 (en) 2004-05-28 2010-07-20 Isis Pharmaceuticals, Inc. Identification of novel pathways, genes and promoter motifs regulating adipogenesis
JP2008501693A (ja) 2004-06-03 2008-01-24 アイシス ファーマシューティカルズ、インク. 遺伝子調節で使用するための個別に調節された鎖を有する二本鎖組成物
EP4047096A1 (en) 2004-06-28 2022-08-24 The University Of Western Australia Antisense oligonucleotides for inducing exon skipping and methods of use thereof
PT2409713E (pt) 2004-08-10 2015-10-09 Genzyme Corp Oligonucleótidos para utilização em modulação dos níveis de lipoproteínas e colesterol em humanos
EP1795536B1 (en) 2004-08-26 2012-05-02 Nippon Shinyaku Co., Ltd. Phosphoramidite compound and method for producing oligo-rna
WO2006029258A2 (en) 2004-09-07 2006-03-16 Archemix Corp. Aptamer medicinal chemistry
US7884086B2 (en) 2004-09-08 2011-02-08 Isis Pharmaceuticals, Inc. Conjugates for use in hepatocyte free uptake assays
US20090203132A1 (en) 2004-09-09 2009-08-13 Swayze Eric E Pyrrolidinyl groups for attaching conjugates to oligomeric compounds
EP2397563A3 (en) 2004-09-17 2012-07-18 Isis Pharmaceuticals, Inc. Enhanced antisense oligonucleotides
WO2006044531A2 (en) 2004-10-13 2006-04-27 Isis Parmaceuticals, Inc. Antisense modulation of ptp1b expression
US8212012B2 (en) 2004-11-03 2012-07-03 University Of Kansas Novobiocin analogues having modified sugar moieties
US8212011B2 (en) 2004-11-03 2012-07-03 University Of Kansas Novobiocin analogues
US7622451B2 (en) 2004-11-03 2009-11-24 University Of Kansas Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders
WO2010096650A1 (en) 2009-02-20 2010-08-26 University Of Kansas Novobiocin analogues having modified sugar moieties
US9120774B2 (en) 2004-11-03 2015-09-01 University Of Kansas Novobiocin analogues having modified sugar moieties
US7608594B2 (en) 2004-11-03 2009-10-27 University Of Kansas Novobiocin analogues as anticancer agents
KR100721928B1 (ko) 2004-11-05 2007-05-28 주식회사 바이오씨에스 CpG 올리고데옥시뉴클레오티드를 함유하는 피부질환의치료 또는 예방용 약학적 조성물
EP1657307A1 (en) 2004-11-16 2006-05-17 Immunotech S.A. Oligonucleotides that induce the secretion of GM-CSF
JP4981681B2 (ja) 2004-12-09 2012-07-25 アルナイラム ファーマシューティカルズ, インコーポレイテッド 哺乳類における免疫応答誘導組成物および方法、ならびに短鎖干渉rnaなどのオリゴヌクレオチド剤に対する免疫応答の回避方法
US9809824B2 (en) 2004-12-13 2017-11-07 The United States Of America, Represented By The Secretary, Department Of Health And Human Services CpG oligonucleotide prodrugs, compositions thereof and associated therapeutic methods
WO2006066260A2 (en) 2004-12-17 2006-06-22 Thiosense, Inc. Compositions of and methods for producing phosphorus-chiral monomers and oligomers
US20070099851A1 (en) 2004-12-30 2007-05-03 Linn Gregory S Stable analogues of ribose-1-phosphate and methods for treating diabetes and other metabolic disorders
US20060183763A1 (en) 2004-12-31 2006-08-17 Pfizer Inc Novel pyrrolidyl derivatives of heteroaromatic compounds
JP4836145B2 (ja) 2005-01-28 2011-12-14 クウォン,ヒュン−ジョ マイコバクテリアに由来する、免疫機能刺激用、免疫疾患治療用、アトピー性皮膚炎治療用および/または正常免疫細胞保護用オリゴヌクレオチド
AU2006216493A1 (en) 2005-02-24 2006-08-31 Coley Pharmaceutical Gmbh Immunostimulatory oligonucleotides
CN101189249B (zh) 2005-04-01 2013-04-17 加利福尼亚大学董事会 膦酰基-戊-2-烯-1-基核苷和类似物
DE602006004578D1 (de) 2005-05-05 2009-02-12 Antisense Pharma Gmbh Verwendung von tgf-beta2 antisense oligonukleotiden
WO2006121960A2 (en) 2005-05-06 2006-11-16 Medtronic, Inc. Methods and sequences to suppress primate huntington gene expression
US7902352B2 (en) 2005-05-06 2011-03-08 Medtronic, Inc. Isolated nucleic acid duplex for reducing huntington gene expression
PT3308788T (pt) 2005-06-23 2019-01-30 Cold Spring Harbor Laboratory Composições e métodos para a modulação do splicing de smn2
US9133517B2 (en) 2005-06-28 2015-09-15 Medtronics, Inc. Methods and sequences to preferentially suppress expression of mutated huntingtin
ATE522626T1 (de) 2005-06-28 2011-09-15 Medtronic Inc Verfahren und nukleotid-sequenzen, die bevorzugt die expression eines mutierten huntingtin-genes unterdrücken
US20090162316A1 (en) 2005-07-05 2009-06-25 Harvard University Liver targeted conjugates
JP4984634B2 (ja) 2005-07-21 2012-07-25 ソニー株式会社 物理情報取得方法および物理情報取得装置
DK1924252T3 (da) 2005-07-28 2011-11-14 Id Fish Technology Inc Fremgangsmåde til forbedring af cellepermeabilitet for fremmede partikler
AU2006284855B2 (en) 2005-08-29 2011-10-13 Regulus Therapeutics Inc. Methods for use in modulating miR-122a
EP1937312B1 (en) 2005-08-30 2016-06-29 Ionis Pharmaceuticals, Inc. Chimeric oligomeric compounds for modulation of splicing
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
US20070077993A1 (en) 2005-09-30 2007-04-05 Midgley Timothy M Method and apparatus for collecting user game play data and crediting users in a gaming environment
AU2006304205C1 (en) 2005-10-12 2012-11-15 Idera Pharmaceuticals, Inc. Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
US9308252B2 (en) 2005-10-27 2016-04-12 Cook Biotech, Inc. Extracellular matrix materials as vaccine adjuvants for diseases associated with infectious pathogens or toxins
JP5111385B2 (ja) 2005-10-28 2013-01-09 アルナイラム ファーマシューティカルズ, インコーポレイテッド ハンチンチン遺伝子の発現を抑制するための組成物および方法
CN101466834B (zh) 2005-10-28 2013-09-25 东曹株式会社 制备类胡萝卜素合成性微生物的方法和生产类胡萝卜素的方法
RU2008118144A (ru) 2005-11-11 2009-11-20 Пфайзер Инк. (US) Комбинации иммуномодулирующих олигоодезоксинуклеотидов и способы их применения
WO2007064291A1 (en) 2005-11-30 2007-06-07 Jyoti Chattopadhyaya Method and compounds for rna synthesis
WO2007064954A2 (en) 2005-12-02 2007-06-07 Isis Pharmaceuticals, Inc. Antibacterial 4,5-substituted aminoglycoside analogs having multiple substituents
US8076303B2 (en) 2005-12-13 2011-12-13 Spring Bank Pharmaceuticals, Inc. Nucleotide and oligonucleotide prodrugs
DK1979356T3 (da) 2005-12-21 2013-11-18 Pfizer Prod Inc Carbonylaminopyrrolopyrazoler, kraftige kinaseinhibitorer
JP5425474B2 (ja) 2006-01-26 2014-02-26 アイシス ファーマシューティカルズ, インコーポレーテッド ハンチンチン対する、組成物及びその使用
ES2516815T3 (es) 2006-01-27 2014-10-31 Isis Pharmaceuticals, Inc. Análogos de ácidos nucleicos bicíclicos modificados en la posición 6
US20080045473A1 (en) 2006-02-15 2008-02-21 Coley Pharmaceutical Gmbh Compositions and methods for oligonucleotide formulations
JP4713514B2 (ja) 2006-02-20 2011-06-29 エフ.ホフマン−ラ ロシュ アーゲー 改善された標識試薬
US8383660B2 (en) 2006-03-10 2013-02-26 Pfizer Inc. Dibenzyl amine compounds and derivatives
CA2647827A1 (en) 2006-03-31 2007-10-11 Applied Biosystems Inc. Reagents useful for synthesizing rhodamine-labeled oligonucleotides
US8088582B2 (en) 2006-04-06 2012-01-03 Ibis Biosciences, Inc. Compositions for the use in identification of fungi
CA2649636A1 (en) 2006-04-20 2007-11-01 F. Hoffmann-La Roche Ag Diazepan derivatives modulators of chemokine receptors
EP2020449B1 (en) 2006-04-24 2012-09-26 Sigma Alimentos, S.A. De C.V. Method for detection and multiple, simultaneous quantification of pathogens by means of real-time polymerase chain reaction
AU2007243412A1 (en) 2006-04-25 2007-11-08 Immune Disease Institute Inc. Targeted delivery to leukocytes using non-protein carriers
GB0608838D0 (en) 2006-05-04 2006-06-14 Novartis Ag Organic compounds
US8158598B2 (en) 2006-05-05 2012-04-17 Isis Pharmaceuticals, Inc. Compositions and their uses directed to PTPR alpha
WO2007131237A2 (en) 2006-05-05 2007-11-15 Isis Pharmaceuticals, Inc. Compounds and methods for modulating expression of ptp1b
US20090012120A1 (en) 2006-05-10 2009-01-08 Board Of Trustees Of Michigan State University Synthesis of N-heterocycles, beta-amino acids, and allyl amines via aza-payne mediated reaction of ylides and hydroxy aziridines
US7666854B2 (en) 2006-05-11 2010-02-23 Isis Pharmaceuticals, Inc. Bis-modified bicyclic nucleic acid analogs
ES2389737T3 (es) 2006-05-11 2012-10-31 Isis Pharmaceuticals, Inc. Análogos de ácidos nucleicos bicíclicos modificados en 5'
WO2007139190A1 (ja) 2006-05-31 2007-12-06 Toray Industries, Inc. 免疫刺激オリゴヌクレオチド及びその医薬用途
US8097596B2 (en) 2006-06-30 2012-01-17 Lakewood-Amedex, Inc. Compositions and methods for the treatment of muscle wasting
AU2007272906B2 (en) 2006-07-12 2013-01-31 The Regents Of The University Of California Transducible delivery of nucleic acids by reversible phosphotriester charge neutralization protecting groups
EP2051977A2 (en) 2006-07-20 2009-04-29 Amgen Inc. SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF LLbeta-HSD-1
GB0614947D0 (en) 2006-07-27 2006-09-06 Isis Innovation Epitope reduction therapy
CA2660052A1 (en) 2006-08-04 2008-02-07 Isis Pharmaceuticals, Inc. Compositions and methods for the modulation of jnk proteins
AT504194B1 (de) 2006-09-07 2008-07-15 Oesterr Rotes Kreuz Bakteriennachweis
US8138330B2 (en) 2006-09-11 2012-03-20 Sigma-Aldrich Co. Llc Process for the synthesis of oligonucleotides
PT2078080E (pt) 2006-09-27 2015-09-18 Coley Pharm Gmbh Análogos dos oligonucleotídeos cpg que contêm análogos t hidrofóbicos com atividade imunoestimulante potenciada
EP2410053B2 (en) 2006-10-18 2020-07-15 Ionis Pharmaceuticals, Inc. Antisense compounds
WO2008051763A1 (en) 2006-10-23 2008-05-02 Irm Llc Cathepsin proteases inhibitors
CA2667297A1 (en) 2006-10-26 2008-11-20 Coley Pharmaceutical Gmbh Oligoribonucleotides and uses thereof
FR2908414B1 (fr) 2006-11-13 2012-01-20 Centre Nat Rech Scient Immobilisation de proteines membranaires sur un support par l'intermediaire d'une molecule amphiphile
CA2669917A1 (en) 2006-11-17 2008-05-22 Dawn M. George Aminopyrrolidines as chemokine receptor antagonists
US8084437B2 (en) 2006-11-27 2011-12-27 Isis Pharmaceuticals, Inc. Methods for treating hypercholesterolemia
US8093222B2 (en) 2006-11-27 2012-01-10 Isis Pharmaceuticals, Inc. Methods for treating hypercholesterolemia
MX2009006230A (es) 2006-12-12 2009-06-22 Idera Pharmaceuticals Inc Agonistas sinteticos de receptores de tipo toll 9.
UY30892A1 (es) 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
WO2008101157A1 (en) 2007-02-15 2008-08-21 Isis Pharmaceuticals, Inc. 5'-substituted-2'-f modified nucleosides and oligomeric compounds prepared therefrom
AU2008230886B9 (en) 2007-03-24 2014-09-04 Kastle Therapeutics, Llc Administering antisense oligonucleotides complementary to human apolipoprotein B
US7960353B2 (en) 2007-05-10 2011-06-14 University Of Kansas Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders
DK2158316T3 (en) 2007-05-11 2015-07-20 Adynxx Inc Gene expression and pain
EP2149571A4 (en) 2007-05-24 2010-09-01 Kyorin Seiyaku Kk MUTILINE DERIVATIVE WITH A RINGED, HETEROCYCLIC AND AROMATIC CARBOXYLIC ACID STRUCTURE IN A SUBSTITUTE AT POSITION 14
GB0710186D0 (en) 2007-05-29 2007-07-04 Texas Instr Denmark PWM loop with minimum allasing error property
ES2388590T3 (es) 2007-05-30 2012-10-16 Isis Pharmaceuticals, Inc. Análogos de ácidos nucleicos bicíclicos con puente aminometileno N-sustituido.
KR20100038295A (ko) 2007-06-05 2010-04-14 엔에스아베 필리알 아프 뉴로서치 스웨덴 아베 스베리게 피질 카테콜아민성 신경 전달의 조정자로서의 이치환된 페닐피롤리딘
DK2173760T4 (en) 2007-06-08 2016-02-08 Isis Pharmaceuticals Inc Carbocyclic bicyclic nukleinsyreanaloge
US20100298280A1 (en) 2007-06-13 2010-11-25 Petra Kioschis-Schneider Compounds for the Modulation of Huntingtin Aggregation, Methods and Means for Identifying Such Compounds
EP2014769B1 (en) 2007-06-18 2010-03-31 Commissariat à l'Energie Atomique Reversible siRNAa-based silencing of mutated and endogenous wild-type huntingtin gene and its application for the treatment of Huntington's disease
GB0712494D0 (en) 2007-06-27 2007-08-08 Isis Innovation Substrate reduction therapy
DK2176280T4 (en) 2007-07-05 2015-07-20 Isis Pharmaceuticals Inc 6-Disubstituerede bicykliske nukleinsyreanaloge
EP2348112B1 (en) 2007-07-09 2018-11-28 Idera Pharmaceuticals, Inc. Stabilized immune modulatory RNA (SIMRA) compounds
TWI413530B (zh) 2007-07-20 2013-11-01 Kao Corp 有機聚矽氧
WO2009015479A1 (en) 2007-07-31 2009-02-05 University Of Saskatchewan Genetic variation in pro-melanin-concentrating hormone gene affects carcass traits in cattle
US7812003B2 (en) 2007-08-02 2010-10-12 Safe Stephen H Antisense microRNA and uses therefor
JP2010536787A (ja) 2007-08-15 2010-12-02 イデラ ファーマシューティカルズ インコーポレイテッド Toll様受容体モジュレータ
WO2009046141A2 (en) 2007-10-01 2009-04-09 Isis Pharmaceuticals, Inc. Antisense modulation of fibroblast growth factor receptor 4 expression
KR100886139B1 (ko) 2007-11-13 2009-02-27 주식회사 삼천리제약 올리고뉴클레오타이드의 제조방법
TW200930375A (en) 2007-12-21 2009-07-16 Exelixis Inc Benzofuropyrimidinones
TWI340765B (en) 2007-12-26 2011-04-21 Ind Tech Res Inst Oligonucleotide sequences and dna chip for identifying filamentous microorganisms and the identification method thereof
WO2009089659A1 (en) 2008-01-18 2009-07-23 Shanghai Targetdrug Co., Ltd. Pyrollidine-based compounds
WO2009098197A1 (en) 2008-02-04 2009-08-13 Biofocus Dpi B.V. Target sequences and methods to identify the same, useful in treatment of neurodegenerative diseases
JP2009190983A (ja) 2008-02-12 2009-08-27 Tokyo Institute Of Technology オリゴヌクレオチド誘導体
EP2282744B1 (en) 2008-03-21 2018-01-17 Ionis Pharmaceuticals, Inc. Oligomeric compounds comprising tricyclic nucleosides and methods for their use
WO2009120878A2 (en) 2008-03-26 2009-10-01 Alnylam Pharmaceuticals, Inc. Non-natural ribonucleotides, and methods of use thereof
KR101806314B1 (ko) 2008-04-03 2017-12-07 스프링 뱅크 파마슈티칼스, 인크. 바이러스 감염증을 치료하기 위한 조성물 및 방법
WO2009124238A1 (en) 2008-04-04 2009-10-08 Isis Pharmaceuticals, Inc. Oligomeric compounds comprising neutrally linked terminal bicyclic nucleosides
US8350022B2 (en) 2008-04-04 2013-01-08 Universitaet Hamburg Method for the stereoselective synthesis of phosphorus compounds
US8679750B2 (en) 2008-05-09 2014-03-25 The University Of British Columbia Methods and compositions for the treatment of Huntington'S disease
CA2726866A1 (en) 2008-05-09 2009-11-12 The University Of British Columbia Methods and compositions for the treatment of huntington's disease
EP2300102B1 (en) 2008-05-15 2014-01-08 Dynavax Technologies Corporation Immunostimulatory sequences containing CpG for use in the treatment of allergic rhinitis
WO2009143387A2 (en) 2008-05-22 2009-11-26 Isis Pharmaceuticals, Inc. Modulation of smrt expression
WO2009143391A2 (en) 2008-05-22 2009-11-26 Isis Pharmaceuticals, Inc Methods for modulation expression of creb
WO2009143390A2 (en) 2008-05-22 2009-11-26 Isis Pharmaceuticals, Inc. Methods for modulating expression of rbp4
WO2009148605A2 (en) 2008-06-04 2009-12-10 Isis Pharmaceuticals, Inc. Methods for treating hypercholesterolemia
AU2009266806A1 (en) 2008-07-03 2010-01-07 Exelixis Inc. CDK modulators
US8410070B2 (en) 2008-09-12 2013-04-02 University Of Louisville Research Foundation, Inc. Compositions and methods for treating cancer, inhibiting proliferation, and inducing cell death
US8163707B2 (en) 2008-09-15 2012-04-24 Enanta Pharmaceuticals, Inc. 4′-allene-substituted nucleoside derivatives
WO2010039543A2 (en) 2008-09-23 2010-04-08 Traversa Therapeutics, Inc. Self delivering bio-labile phosphate protected pro-oligos for oligonucleotide based therapeutics and mediating rna interference
WO2010036696A1 (en) 2008-09-24 2010-04-01 Isis Pharmaceuticals, Inc. Cyclohexenyl nucleic acid analogs
EP2356129B1 (en) 2008-09-24 2013-04-03 Isis Pharmaceuticals, Inc. Substituted alpha-l-bicyclic nucleosides
JP2012504962A (ja) 2008-10-07 2012-03-01 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ テロメラーゼ阻害剤およびその使用方法
DK2350279T3 (en) 2008-10-22 2016-02-15 Quark Pharmaceuticals Inc METHODS OF TREATING EYE DISEASES
US8883752B2 (en) 2008-10-24 2014-11-11 Isis Pharmaceuticals, Inc. 5′ and 2′ BIS-substituted nucleosides and oligomeric compounds prepared therefrom
WO2010048585A2 (en) 2008-10-24 2010-04-29 Isis Pharmaceuticals, Inc. Oligomeric compounds and methods
WO2010064146A2 (en) 2008-12-02 2010-06-10 Chiralgen, Ltd. Method for the synthesis of phosphorus atom modified nucleic acids
JP2012513450A (ja) 2008-12-23 2012-06-14 ギリンダス・アメリカ・インコーポレイテッド 硫化剤およびオリゴヌクレオチドを合成するためのその使用
WO2010080953A1 (en) 2009-01-08 2010-07-15 Isis Pharmaceuticals, Inc. Transgenic murine model of human lipoprotein metabolism, hypercholesterolemia and cardiovascular disease
KR20100087540A (ko) 2009-01-28 2010-08-05 삼성전자주식회사 잉크젯 기록용 잉크 조성물
WO2010091301A1 (en) 2009-02-06 2010-08-12 Isis Pharmaceuticals, Inc. Oligomeric compounds and excipients
EP2396409A2 (en) 2009-02-10 2011-12-21 Idera Pharmaceuticals, Inc. Synthetic rna-based agonists of tlr7
US8975389B2 (en) 2009-03-02 2015-03-10 Alnylam Pharmaceuticals, Inc. Nucleic acid chemical modifications
WO2010107838A1 (en) 2009-03-16 2010-09-23 Isis Pharmaceuticals, Inc. Targeting apolipoprotein b for the reduction of apolipoprotein c-iii
DK2415777T3 (en) 2009-03-31 2015-08-24 Takeda Pharmaceutical A process for the preparation of nucleoside
US8987222B2 (en) 2009-04-08 2015-03-24 University Of Massachusetts Single nucleotide polymorphism (SNP) targeting therapies for the treatment of huntington'S disease
US20120156138A1 (en) 2009-04-14 2012-06-21 Smith Larry J Methods and Compositions for the Treatment of Medical Conditions Involving Cellular Reprogramming
WO2010129853A2 (en) 2009-05-07 2010-11-11 The Regents Of The University Of California TRANSDUCIBLE DELIVERY OF NUCLEIC ACIDS USING MODIFIED dsRNA BINDING DOMAINS
CN102459302A (zh) 2009-06-01 2012-05-16 加利福尼亚大学董事会 核酸递送组合物及其使用方法
CA2764374C (en) 2009-06-05 2019-11-19 Infectious Disease Research Institute Synthetic glucopyranosyl lipid adjuvants
JP5707396B2 (ja) 2009-06-17 2015-04-30 アイシス ファーマシューティカルズ, インコーポレーテッド 被験体におけるsmn2スプライシングのモジュレーションのための組成物および方法
JP5670097B2 (ja) 2009-06-19 2015-02-18 花王株式会社 二層分離型毛髪化粧料
US20120108800A1 (en) 2009-06-23 2012-05-03 Shumpei Murata Method for synthesizing nucleic acid
US8329024B2 (en) 2009-07-06 2012-12-11 Ada Technologies, Inc. Electrochemical device and method for long-term measurement of hypohalites
RU2612521C2 (ru) 2009-07-06 2017-03-09 Онтории, Инк. Новые пролекарства нуклеиновых кислот и способы их применения
WO2011005860A2 (en) 2009-07-07 2011-01-13 Alnylam Pharmaceuticals, Inc. 5' phosphate mimics
US20110009477A1 (en) 2009-07-08 2011-01-13 Idera Pharmaceuticals, Inc. Oligonucleotide-based compounds as inhibitors of toll-like receptors
EP2458005A1 (en) 2009-07-23 2012-05-30 Galaxy Pharma Inc. Fgf21 cis-element binding substance
WO2011015572A1 (en) 2009-08-03 2011-02-10 Galapagos Nv Molecular targets and compounds, and methods to identify the same, useful in the treatment of neurodegenerative diseases
WO2011015573A1 (en) 2009-08-03 2011-02-10 Galapagos Nv Molecular targets and compounds, and methods to identify the same, useful in the treatment of neurodegenerative diseases
UA107360C2 (en) 2009-08-05 2014-12-25 Biogen Idec Inc Bicyclic aryl sphingosine 1-phosphate analogs
US9012421B2 (en) 2009-08-06 2015-04-21 Isis Pharmaceuticals, Inc. Bicyclic cyclohexose nucleic acid analogs
US8927553B2 (en) 2009-08-10 2015-01-06 Daljit Singh Dhanoa Deuterium-enriched alkyl sulfonamides and uses thereof
NZ624783A (en) 2009-09-11 2015-12-24 Isis Pharmaceuticals Inc Modulation of huntingtin expression
EP2479182B8 (en) 2009-09-16 2016-07-13 Wave Life Sciences Japan, Inc. Novel protecting group for synthesizing rna and derivative thereof
WO2011038288A1 (en) 2009-09-25 2011-03-31 Isis Pharmaceuticals, Inc. Modulation of ttc39 expression to increase hdl
ES2426407T3 (es) 2009-10-15 2013-10-23 Pfizer Inc. Compuestos de pirrolo[2,3-d]pirimidina
TWI475051B (zh) 2009-11-18 2015-03-01 Kao Corp Organic polysiloxane
JP5809408B2 (ja) 2009-11-25 2015-11-10 花王株式会社 毛髪化粧料
US8735417B2 (en) 2009-12-17 2014-05-27 Merck Sharp & Dohme Corp. Aminopyrimidines as Syk inhibitors
BR112012016912A2 (pt) 2009-12-28 2016-04-05 Achira Labs Pvt Ltd composição de gel de diagnóstico, método para preparar uma composição de gel de diagnóstico
CN111700901A (zh) 2010-01-08 2020-09-25 Ionis制药公司 血管生成素样3表达的调节
US8750507B2 (en) 2010-01-25 2014-06-10 Cisco Technology, Inc. Dynamic group creation for managed key servers
EP3561060A1 (en) 2010-02-08 2019-10-30 Ionis Pharmaceuticals, Inc. Selective reduction of allelic variants
AU2011213563B2 (en) 2010-02-08 2015-12-24 Ionis Pharmaceuticals, Inc. Selective reduction of allelic variants
RS53745B1 (en) 2010-02-10 2015-06-30 Glaxosmithkline Llc 6-AMINO-2 - {[(1S) -1-METYLBUTIL] OKSI} -9- [5- (1-PIPERIDINIL) PENTIL] -7,9-DIHIDRO-8H-PURIN-8-ON-MALEAT
US8859755B2 (en) 2010-03-05 2014-10-14 Chiralgen, Ltd. Method for preparing ribonucleoside phosphorothioate
WO2011127175A1 (en) 2010-04-06 2011-10-13 Isis Pharmaceuticals, Inc. Modulation of cd130 (gp130) expression
CA2795750A1 (en) 2010-04-07 2011-10-13 Isis Pharmaceuticals, Inc. Modulation of cetp expression
WO2011133871A2 (en) 2010-04-22 2011-10-27 Alnylam Pharmaceuticals, Inc. 5'-end derivatives
EP2625186B1 (en) 2010-04-28 2016-07-27 Ionis Pharmaceuticals, Inc. 5' modified nucleosides and oligomeric compounds prepared therefrom
CN103154014B (zh) 2010-04-28 2015-03-25 Isis制药公司 修饰核苷、其类似物以及由它们制备的寡聚化合物
US20130156845A1 (en) 2010-04-29 2013-06-20 Alnylam Pharmaceuticals, Inc. Lipid formulated single stranded rna
EP2563921B1 (en) 2010-04-30 2016-11-23 Cellectis Method for modulating double-strand break-induced homologous recombination
GB201008902D0 (en) 2010-05-27 2010-07-14 Imp Innovations Ltd Membrane enhanced polymer sythesis
EP3406730B1 (en) 2010-08-31 2022-02-23 Sirna Therapeutics, Inc. Novel single chemical entities and methods for delivery of oligonucleotides
JP5868324B2 (ja) 2010-09-24 2016-02-24 株式会社Wave Life Sciences Japan 不斉補助基
JP5996431B2 (ja) 2010-09-30 2016-09-21 Lsipファンド運営合同会社 優性変異遺伝子発現抑制剤
KR101381048B1 (ko) 2010-10-20 2014-04-14 씨제이제일제당 (주) O-포스포세린 생산 균주 및 이로부터 생산된 o-포스포세린으로부터 l-시스테인 또는 이의 유도체의 생산방법
EP3766975A1 (en) 2010-10-29 2021-01-20 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina)
DK2638163T3 (en) 2010-11-12 2017-07-24 Massachusetts Gen Hospital POLYCOMB-ASSOCIATED NON-CODING RNAs
JP6093924B2 (ja) 2010-11-30 2017-03-15 株式会社Wave Life Sciences Japan 2’−o−修飾rna
US20140050778A1 (en) 2010-12-28 2014-02-20 University Of Rochester Nucleic acid binding compounds, methods of making, and use thereof
EP3467109A1 (en) 2011-02-08 2019-04-10 Ionis Pharmaceuticals, Inc. Oligomeric compounds comprising bicyclic nucleotides and uses thereof
US9181544B2 (en) 2011-02-12 2015-11-10 University Of Iowa Research Foundation Therapeutic compounds
WO2012151324A1 (en) 2011-05-02 2012-11-08 Isis Pharmaceuticals, Inc. Antisense compounds targeting genes associated with usher syndrome
FR2975600B1 (fr) 2011-05-24 2013-07-05 Assist Publ Hopitaux De Paris Agents pour le traitement de tumeurs
SG10201700554VA (en) 2011-07-19 2017-03-30 Wave Life Sciences Pte Ltd Methods for the synthesis of functionalized nucleic acids
AR088140A1 (es) 2011-07-19 2014-05-14 Univ Idaho Sonda y metodo para direccionar acidos nucleicos
DK2742135T4 (da) 2011-08-11 2020-07-13 Ionis Pharmaceuticals Inc Bindingsmodificerede gapped oligomeriske forbindelser og anvendelser deraf
WO2013033223A1 (en) 2011-08-29 2013-03-07 Isis Pharmaceuticals, Inc. Methods and compounds useful in conditions related to repeat expansion
US20140080896A1 (en) 2011-08-30 2014-03-20 The Regents Of The University Of California Identification of small molecules that facilitate therapeutic exon skipping
EP2751284B1 (en) 2011-08-31 2017-01-11 The University Of Manchester Method for diagnosing a neurodegenerative disease.
US20140255936A1 (en) 2011-09-09 2014-09-11 Mayo Foundation For Medical Education And Research Detecting frontotemporal dementia and amyotrophic lateral sclerosis
EP3858847A1 (en) 2011-11-30 2021-08-04 Sarepta Therapeutics, Inc. Oligonucleotides for treating expanded repeat diseases
KR200460641Y1 (ko) 2011-12-07 2012-06-04 이형호 휴대가 용이한 와인 잔
CA2895077A1 (en) 2011-12-12 2013-06-20 Beverly Packard In vivo delivery of oligonucleotides
IN2014CN04590A (es) 2011-12-16 2015-09-18 Nat Univ Corp Tokyo Med & Dent
CN102675386B (zh) 2011-12-24 2014-07-02 河南科技大学 一种龙胆苦苷分离提纯方法
WO2013134558A1 (en) 2012-03-07 2013-09-12 The Texas A & M University System Cancer treatment targeting non-coding rna overexpression
KR102068856B1 (ko) 2012-03-13 2020-01-21 길리애드 사이언시즈, 인코포레이티드 항바이러스 치료를 위한 2'-치환된 카바-뉴클레오시드 유사체
KR20130114435A (ko) 2012-04-09 2013-10-17 삼성전자주식회사 다수의 전극을 갖는 생분자 검출 장치
PT2841578T (pt) 2012-04-23 2017-08-10 Biomarin Tech Bv Resumo
NZ702744A (en) 2012-05-22 2016-12-23 Idenix Pharmaceuticals Llc D-amino acid compounds for liver disease
US9284344B2 (en) 2012-05-30 2016-03-15 Hokkaido System Science Co., Ltd. Oligonucleotide synthesis method using highly dispersible liquid-phase support
WO2014010250A1 (en) 2012-07-13 2014-01-16 Chiralgen, Ltd. Asymmetric auxiliary group
WO2014012081A2 (en) 2012-07-13 2014-01-16 Ontorii, Inc. Chiral control
US9617547B2 (en) 2012-07-13 2017-04-11 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant
EP2879718B1 (en) 2012-08-06 2023-06-07 Alnylam Pharmaceuticals, Inc. Processes for the preparation of carbohydrate conjugated rna agents
WO2014028739A1 (en) 2012-08-15 2014-02-20 Isis Pharmaceuticals, Inc. Method of preparing oligomeric compounds using modified capping protocols
EP3459549B1 (en) 2012-10-12 2022-04-06 Ionis Pharmaceuticals, Inc. Selective antisense compounds and uses thereof
FI2906696T4 (fi) 2012-10-15 2023-03-18 Menetelmiä c9orf72:n ilmentymisen moduloimiseksi
EP2906258A4 (en) 2012-10-15 2016-08-10 Ionis Pharmaceuticals Inc COMPOSITIONS FOR MODULATING THE EXPRESSION OF C90RF72
US10577604B2 (en) 2012-10-15 2020-03-03 Ionis Pharmaceuticals, Inc. Methods for monitoring C9ORF72 expression
CA2889717A1 (en) 2012-10-29 2014-05-08 Cocrystal Pharma, Inc. Pyrimidine nucleotides and their monophosphate prodrugs for treatment of viral infections and cancer
EP2725029A1 (en) 2012-10-29 2014-04-30 Laboratoire Biodim New antibacterial compounds and biological applications thereof
JP6358955B2 (ja) 2012-10-31 2018-07-18 武田薬品工業株式会社 新規修飾核酸
SG10201804331TA (en) 2012-11-15 2018-07-30 Roche Innovation Ct Copenhagen As Oligonucleotide conjugates
EP2922955B1 (en) 2012-11-26 2019-03-06 Roche Innovation Center Copenhagen A/S Compositions and methods for modulation of fgfr3 expression
WO2014099941A1 (en) 2012-12-19 2014-06-26 Idenix Pharmaceuticals, Inc. 4'-fluoro nucleosides for the treatment of hcv
WO2014118272A1 (en) 2013-01-30 2014-08-07 Santaris Pharma A/S Antimir-122 oligonucleotide carbohydrate conjugates
RU2018108405A (ru) 2013-01-30 2019-02-26 Ф. Хоффманн-Ля Рош Аг Конъюгаты углевода и lna-олигонуклеотида
ES2817050T3 (es) 2013-02-04 2021-04-06 Ionis Pharmaceuticals Inc Compuestos antisentido selectivos y usos de los mismos
EP2958998B1 (en) 2013-02-22 2017-12-27 Sirna Therapeutics, Inc. Short interfering nucleic acid (sina) molecules containing a 2' internucleoside linkage
CN105008533A (zh) 2013-03-01 2015-10-28 国立大学法人东京医科齿科大学 嵌合单链反义多核苷酸和双链反义试剂
MX2015013628A (es) 2013-03-28 2016-02-18 Syngenta Ltd Metodos para controlar las plagas resistentes a neonicotinoides.
EA201500984A1 (ru) 2013-03-28 2016-04-29 Зингента Партисипейшнс Аг Способы контроля устойчивых к неоникотиноидам вредителей
JP6995478B2 (ja) 2013-05-01 2022-01-14 アイオーニス ファーマシューティカルズ, インコーポレーテッド Hbvおよびttr発現を調節するための組成物および方法
WO2014189142A1 (ja) 2013-05-24 2014-11-27 味の素株式会社 モルフォリノオリゴヌクレオチドの製造方法
CN105247052A (zh) 2013-05-24 2016-01-13 罗氏创新中心哥本哈根有限公司 B-细胞cll/淋巴瘤11a(bcl11a)的寡核苷酸调节剂及其用途
WO2014192310A1 (en) 2013-05-30 2014-12-04 National University Corporation Tokyo Medical And Dental University Double-stranded agents for delivering therapeutic oligonucleotides
JP6604544B2 (ja) 2013-06-16 2019-11-13 国立大学法人 東京医科歯科大学 エクソンスキッピング効果を有する二本鎖アンチセンス核酸
JP6694382B2 (ja) 2013-06-21 2020-05-13 アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. 標的核酸を調節するための組成物および方法
DK3013959T3 (da) 2013-06-27 2020-02-17 Roche Innovation Ct Copenhagen As Antisense-oligomerer og konjugater målrettet pcsk9
TWI772856B (zh) 2013-07-19 2022-08-01 美商百健Ma公司 用於調節τ蛋白表現之組合物
WO2015013673A1 (en) 2013-07-25 2015-01-29 Aurasense Therapeutics, Llc Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
US10435430B2 (en) 2013-07-31 2019-10-08 Ionis Pharmaceuticals, Inc. Methods and compounds useful in conditions related to repeat expansion
CN105579442A (zh) 2013-09-06 2016-05-11 先正达参股股份有限公司 杀虫化合物
EP3052511A4 (en) 2013-10-02 2017-05-31 Moderna Therapeutics, Inc. Polynucleotide molecules and uses thereof
US10323076B2 (en) 2013-10-03 2019-06-18 Modernatx, Inc. Polynucleotides encoding low density lipoprotein receptor
US9988627B2 (en) 2013-10-04 2018-06-05 Novartis Ag Formats for organic compounds for use in RNA interference
WO2015054676A2 (en) 2013-10-11 2015-04-16 Isis Pharmaceuticals, Inc. Compositions for modulating c9orf72 expression
US20160237432A1 (en) 2013-10-14 2016-08-18 Ionis Pharmaceuticals, Inc. Methods for modulating expression of c9orf72 antisense transcript
WO2015057727A1 (en) 2013-10-14 2015-04-23 Isis Pharmaceuticals, Inc. Compositions for modulating expression of c9orf72 antisense transcript
RU2693891C1 (ru) 2013-11-11 2019-07-05 Сангамо Байосайенсиз, Инк. Способы и композиции для лечения болезни хантингтона
JP2017501684A (ja) 2013-11-14 2017-01-19 ロシュ・イノベーション・センター・コペンハーゲン・アクティーゼルスカブRoche Innovation Center Copenhagen A/S Apobアンチセンスコンジュゲート化合物
US20150167017A1 (en) 2013-12-13 2015-06-18 Moderna Therapeutics, Inc. Alternative nucleic acid molecules and uses thereof
JPWO2015108048A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
WO2015108046A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤
EP3095461A4 (en) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
AU2015207773B2 (en) 2014-01-16 2021-06-17 Wave Life Sciences Ltd. Chiral design
EP4410805A2 (en) 2014-03-18 2024-08-07 University of Massachusetts Raav-based compositions and methods for treating amyotrophic lateral sclerosis
US9926556B2 (en) 2014-04-28 2018-03-27 Ionis Pharmaceuticals, Inc. Linkage modified oligomeric compounds
US9382540B2 (en) 2014-05-01 2016-07-05 Isis Pharmaceuticals, Inc Compositions and methods for modulating angiopoietin-like 3 expression
US11110154B2 (en) 2014-05-08 2021-09-07 Sangamo Therapeutics, Inc. Methods and compositions for treating Huntington's Disease
US9523093B2 (en) 2014-05-20 2016-12-20 University Of Iowa Research Foundation Huntington's disease therapeutic compounds
US20160017327A1 (en) 2014-07-11 2016-01-21 The Johns Hopkins University Phosphorodiamidate morpholino oligomers (pmos) and their use in suppression of mutant huntingtin expression and attenuation of neurotoxicity
JP2017524357A (ja) 2014-07-16 2017-08-31 モデルナティエックス インコーポレイテッドModernaTX,Inc. キメラポリヌクレオチド
EP2982758A1 (en) 2014-08-04 2016-02-10 Centre Hospitalier Universitaire Vaudois (CHUV) Genome editing for the treatment of huntington's disease
ES2799409T3 (es) 2014-08-07 2020-12-17 Takeda Pharmaceuticals Co Lípido catiónico
WO2016024205A1 (en) 2014-08-15 2016-02-18 Pfizer Inc. Oligomers targeting hexanucleotide repeat expansion in human c9orf72 gene
WO2016027168A2 (en) 2014-08-20 2016-02-25 Lifesplice Pharma Llc Splice modulating oligonucleotides and methods of use thereof
WO2016037191A1 (en) 2014-09-05 2016-03-10 Health Research, Inc. Use of huntingtin-derived plasmids and peptides for active immunization as a huntington's disease (hd) therapeutic
EP3221451A1 (en) 2014-11-17 2017-09-27 Alnylam Pharmaceuticals, Inc. Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof
US20180112217A1 (en) 2014-11-19 2018-04-26 Roche Innovation Center Copenhagen A/S Stereospecific Phosphorothioate LNA
WO2016096938A1 (en) 2014-12-16 2016-06-23 Roche Innovation Center Copenhagen A/S Chiral toxicity screening method
EA037696B1 (ru) 2014-12-24 2021-05-12 ЮНИКЕР АйПи Б.В. Супрессия гена гентингтина, индуцированная рнк-интерференцией
US9688707B2 (en) 2014-12-30 2017-06-27 Ionis Pharmaceuticals, Inc. Bicyclic morpholino compounds and oligomeric compounds prepared therefrom
WO2016112132A1 (en) 2015-01-06 2016-07-14 Ionis Pharmaceuticals, Inc. Compositions for modulating expression of c9orf72 antisense transcript
US20180023081A1 (en) 2015-02-04 2018-01-25 Bristol-Myers Squibb Company Lna oligonucleotides with alternating flanks
WO2016127000A1 (en) 2015-02-04 2016-08-11 Bristol-Myers Squibb Company Methods of selecting therapeutic molecules
JP2018505676A (ja) 2015-02-04 2018-03-01 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft タウアンチセンスオリゴマー及びその使用
MY181458A (en) 2015-02-10 2020-12-22 Genzyme Corp Variant rnai
EP3256587A2 (en) 2015-02-13 2017-12-20 Alnylam Pharmaceuticals, Inc. Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
WO2016138017A1 (en) 2015-02-23 2016-09-01 Ionis Pharmaceuticals, Inc. Compounds and methods for increasing antisense activity
WO2016141236A1 (en) 2015-03-03 2016-09-09 Ionis Pharmaceuticals, Inc. Compositions for modulating mecp2 expression
WO2016145142A1 (en) 2015-03-10 2016-09-15 Emory University Nucleotide and nucleoside therapeutics compositions and uses related thereto
WO2016154096A1 (en) 2015-03-20 2016-09-29 Ionis Pharmaceuticals, Inc. Modulation of smggds expression
CN116004624A (zh) 2015-04-03 2023-04-25 马萨诸塞大学 用于靶向亨廷汀mRNA的寡核苷酸化合物
US10851371B2 (en) 2015-04-10 2020-12-01 Ionis Pharmaceuticals, Inc. Modulation of SMN expression
US10407678B2 (en) 2015-04-16 2019-09-10 Ionis Pharmaceuticals, Inc. Compositions for modulating expression of C9ORF72 antisense transcript
KR102104163B1 (ko) 2015-04-16 2020-04-23 아이오니스 파마수티컬즈, 인코포레이티드 C9orf72 발현을 조절하기 위한 조성물
WO2016209862A1 (en) 2015-06-23 2016-12-29 Alnylam Pharmaceuticals, Inc. Glucokinase (gck) irna compositions and methods of use thereof
EP3313989A4 (en) 2015-06-29 2018-12-05 Ionis Pharmaceuticals, Inc. Modified crispr rna and modified single crispr rna and uses thereof
US10494632B2 (en) 2015-07-10 2019-12-03 Alnylam Pharmaceuticals, Inc. Insulin-like growth factor binding protein, acid labile subunit (IGFALS) compositions and methods of use thereof
SG10202006563PA (en) 2015-07-10 2020-08-28 Ionis Pharmaceuticals Inc Modulators of diacyglycerol acyltransferase 2 (dgat2)
DK3324980T3 (da) 2015-07-17 2022-02-14 Alnylam Pharmaceuticals Inc Multimålrettede enkeltenhedskonjugater
MA43072A (fr) 2015-07-22 2018-05-30 Wave Life Sciences Ltd Compositions d'oligonucléotides et procédés associés
US20180216114A1 (en) 2015-07-27 2018-08-02 Alnylam Pharmaceuticals, Inc. Xanthine dehydrogenase (xdh) irna compositions and methods of use thereof
JP6896703B2 (ja) 2015-07-31 2021-06-30 アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. TTR関連疾患を治療または予防するためのトランスサイレチン(TTR)iRNA組成物およびその使用方法
KR20180043819A (ko) 2015-08-24 2018-04-30 로슈 이노베이션 센터 코펜하겐 에이/에스 Lna-g 방법
IL310959A (en) 2015-08-25 2024-04-01 Alnylam Pharmaceuticals Inc Methods and preparations for treating a disorder related to the PCSK9 gene
CN108368507B (zh) 2015-09-02 2022-03-22 阿尔尼拉姆医药品有限公司 程序性细胞死亡1配体1(PD-L1)的iRNA组合物及其使用方法
WO2017048620A1 (en) 2015-09-14 2017-03-23 Alnylam Pharmaceuticals, Inc. Polynucleotide agents targeting patatin-like phospholipase domain containing 3 (pnpla3) and methods of use thereof
US10874686B2 (en) 2015-10-01 2020-12-29 Memorial Sloan-Kettering Cancer Center Anthranilyl-adenosinemonosulfamate analogs and uses thereof
EP3356447A4 (en) 2015-10-01 2019-06-12 Memorial Sloan-Kettering Cancer Center INHIBITORS OF MENACHINONE BIOSYNTHESIS
CN108136041B (zh) 2015-10-02 2022-12-30 罗氏创新中心哥本哈根有限公司 寡核苷酸缀合方法
MX2018003992A (es) 2015-10-09 2018-08-01 Wave Life Sciences Ltd Composiciones oligonucleotidicas y sus metodos.
WO2017067970A1 (en) 2015-10-22 2017-04-27 Roche Innovation Center Copenhagen A/S In vitro toxicity screening assay
WO2017068087A1 (en) 2015-10-22 2017-04-27 Roche Innovation Center Copenhagen A/S Oligonucleotide detection method
WO2017079291A1 (en) 2015-11-02 2017-05-11 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating c90rf72
RU2742007C2 (ru) 2015-11-12 2021-02-01 Ф. Хоффманн-Ля Рош Аг Олигонуклеотиды для индуцирования отцовской экспрессии ube3a
JP7286320B2 (ja) 2016-03-13 2023-06-05 ウェイブ ライフ サイエンシズ リミテッド ホスホラミダイト及びオリゴヌクレオチド合成のための組成物並びに方法
AU2017235278C1 (en) 2016-03-14 2022-03-10 F. Hoffmann-La Roche Ag Oligonucleotides for reduction of PD-L1 expression
EP3430021A1 (en) 2016-03-18 2019-01-23 Roche Innovation Center Copenhagen A/S Acyl-protected l-lna-guanosine monomers
WO2017165489A1 (en) 2016-03-23 2017-09-28 Emory University Antiviral agents for treating zika and dengue virus infections
EP3443094B1 (en) 2016-04-13 2022-10-19 Ionis Pharmaceuticals, Inc. Methods for reducing c9orf72 expression
EP3442983A1 (en) 2016-04-14 2019-02-20 H. Hoffnabb-La Roche Ag TRITYL-MONO-Ga1NAc COMPOUNDS AND THEIR USE
MA45270A (fr) 2016-05-04 2017-11-09 Wave Life Sciences Ltd Compositions d'oligonucléotides et procédés associés
MA45290A (fr) 2016-05-04 2019-03-13 Wave Life Sciences Ltd Procédés et compositions d'agents biologiquement actifs
US11261209B2 (en) 2016-05-12 2022-03-01 Roche Innovation Center Copenhagen A/S Enhanced coupling of stereodefined oxazaphospholidine phosphoramidite monomers to nucleoside or oligonucleotide
US10752891B2 (en) 2016-05-13 2020-08-25 Roche Molecular Systems, Inc. Protein-based sample collection matrices and devices
EP3458464A1 (en) 2016-05-18 2019-03-27 ETH Zurich Stereoselective synthesis of phosphorothioate oligoribonucleotides
EP3463386A4 (en) 2016-06-03 2020-03-04 Wave Life Sciences Ltd. OLIGONUCLEOTIDES, COMPOSITIONS AND METHOD THEREFOR
JP6823269B2 (ja) 2016-06-20 2021-02-03 株式会社GenAhead Bio 抗体−薬物コンジュゲート
US20190264267A1 (en) 2016-07-25 2019-08-29 Wave Life Sciences Ltd. Phasing
CN110088113A (zh) 2016-11-23 2019-08-02 波涛生命科学有限公司 用于亚磷酰胺和寡核苷酸合成的组合物和方法

Also Published As

Publication number Publication date
JP2015205910A (ja) 2015-11-19
AU2010270714A1 (en) 2012-02-16
AU2010270714B2 (en) 2015-08-13
MX2012000380A (es) 2012-05-23
EP2451461A4 (en) 2013-05-29
US20120316224A1 (en) 2012-12-13
IN2012DN00720A (es) 2015-06-19
US10307434B2 (en) 2019-06-04
BR112012000828A2 (pt) 2016-02-23
CN102596204A (zh) 2012-07-18
JP2012532199A (ja) 2012-12-13
SG177564A1 (en) 2012-02-28
WO2011005761A8 (en) 2012-02-02
IL217370A (en) 2017-09-28
BR112012000828A8 (pt) 2017-10-10
RU2012102480A (ru) 2013-08-20
JP5998326B2 (ja) 2016-09-28
EP2451461A1 (en) 2012-05-16
SG10201403841QA (en) 2014-09-26
IL217370A0 (en) 2012-02-29
CN102596204B (zh) 2016-11-23
KR101885383B1 (ko) 2018-08-03
US20160347784A1 (en) 2016-12-01
KR20120046238A (ko) 2012-05-09
US9744183B2 (en) 2017-08-29
RU2612521C2 (ru) 2017-03-09
CA2767253A1 (en) 2011-01-13
CL2012000021A1 (es) 2012-07-20
WO2011005761A1 (en) 2011-01-13

Similar Documents

Publication Publication Date Title
MX342945B (es) Profármacos de ácido nucleico novedosos y métodos de uso de los mismos.
MX2011013421A (es) Arnds formulado con lipido de direccionamiento del gen pcsk9.
SG10201503327QA (en) Production of nucleic acid
MX2012007710A (es) Alfa-amilasas.
GB201209132D0 (en) Compositions and methods for targeted nucleic acid sequence selection and amplification
EP2113570A4 (en) PROCESS FOR PRODUCTION OF L-AMINO ACID
GB0910302D0 (en) Nucleic acid amplification
HK1159250A1 (en) Improved method of rna display rna
EP2595664A4 (en) MODULATION OF NUCLEAR RETENTION RNA
HUE054566T2 (hu) Téglagyártási eljárás enzimtermelõ baktériumok felhasználásával
BRPI1015238A2 (pt) diamidas de azetidilina como inibidores de monoaciglicerol lipase
EP2499166A4 (en) IMPROVED ENZYMATIC HYDROLYSIS METHODS
MX2011011531A (es) Acidos nucleicos que se unen a hepcidina.
EP2294213A4 (en) METHODS FOR MODULATING CREB EXPRESSION
IL216109A0 (en) Production of ammonium phosphates
EP2130924A4 (en) PROCESS FOR PRODUCING L-AMINO ACID OR NUCLEIC ACID
GB0911380D0 (en) Maritube - floating algal cultivation system
EP2405005A4 (en) MICROORGANISM FOR THE MANUFACTURE OF L-AMINO ACIDS AND METHOD FOR THE PRODUCTION OF L-AMINO ACIDS THEREWITH
EP2405006A4 (en) MICROORGANISM FOR THE MANUFACTURE OF L-AMINO ACIDS AND METHOD FOR THE PRODUCTION OF L-AMINO ACIDS THEREWITH
EP2328907A4 (en) HYDROLASES, NUCLEIC ACIDS COORDINATING THEREFOR, AND METHOD FOR THE PRODUCTION AND USE THEREOF
GB0916957D0 (en) Floagal-floating algal cultivation system
EP2195453A4 (en) METHOD FOR AMPLIFYING NUCLEIC ACID
IL217247A0 (en) Dermaseptin b2 as an inhibitor of tumor growth
MX338553B (es) Procesos para la preparacion de enaminas.
MX337042B (es) Procesos para la preparacion de enaminas.

Legal Events

Date Code Title Description
FG Grant or registration